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ABC ATP-binding cassette
ANOVA analysis of variance
5'-AMP adenosine 5'-monophosphate
ATP adenosine triphosphate
BBM brush-border membrane
BLM basolateral membrane
BSA bovine serum albumin
CDDP c/s-diamminedichloroplatin
cDNA complementary DNA
CFTR cystic fibrosis transmembrane conductance regulator
cMOAT canalicular multispecific organic anion transporter
CsA cyclosporin A
DMSO dimethylsulphoxide
DNP-SG 5-(dinitrophenyl)-glucuronide
DTT dithiothreitol
E2175G 17fi-estradiol-17-5-D-glucuronide
EDTA ethylenediamine tetraacetate
EHBR Eisai hyperbilirubinemic rat (Mrp2-deficient Sprague Dawley rat)
FL fluorescein
FL-MTX fluorescein-methotrexate
FURA-AM fura-2 acetoxy methyl ester
GSH reduced glutathione
GSSG oxidized glutathione
GY/TR- Groningen yellow/ Transport deficient rat (Mrp2-deficient Wistar rat)
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulphonic acid
IgG immunoglobulin G
kb kilobases
kDa kilodaltons
Ki inhibition constant
Km Michaelis-Menten constant
LTC4 leukotriene C4
LY lucifer yellow
mAb monoclonal antibody
MDCKII type II (proximal tubule derived) kidney cell line of Madin-Darby canine
MDR multidrug resistance
MK571 3-([{3-(2-[7-chloro-2-quinolinyl]ethenyl)phenyl}-{(3-dimethyl-amino-3- 
oxopropyl)-thio}-methyl]thio)propanoic acid
MOI multiplicity of infection
MRP multidrug resistance protein
MTX methotrexate
OA organic anion
PAGE polyacrylamide gel electrophoresis
PAH para-aminohippurate
PBS phosphate-buffered saline
Pgp P-glycoprotein
PLP periodate lysine paraformaldehyde
PMSF phenyl methyl sulphonyl fluoride
PNGase F N-glycosidase F
PT Proximal tubule
SD standard deviation
SDS sodium dodecyl sulphate
SE standard error of the mean
Sf9 Spodoptera frugiperda cells
TBS tris-buffered saline
TS tris sucrose
Tris Tris(hydroxymethyl)aminomethane
Tween 20 polyoxyethylene sorbitan monolaurate
VBL vinblastine
VCR vincristine
Vmax maximum rate of transport
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Molecular Pharmacology of Renal Organic Anion Transporters
Summary
Renal organic anion transport systems play an important role in the elimination of 
drugs, toxic compounds and their metabolites, many of which are potentially 
harmful to the body. The renal proximal tubule is the primary site of carrier 
mediated transport from blood to urine of a wide variety of anionic substrates. 
Recent studies have shown that organic anion secretion in renal proximal tubule is 
mediated by distinct sodium-dependent and sodium-independent transport 
systems. Knowledge of the molecular identity of these transporters and their 
substrate specificity has increased considerably in the past few years by cloning of 
various carrier proteins. However, a number of fundamental questions still have to 
be answered to elucidate the participation of the cloned transporters in the overall 
tubular secretion of anionic xenobiotics. This review summarizes the latest 
knowledge on molecular and pharmacological properties of renal organic anion 
transporters and homologs, with special reference to their nephron and plasma 
membrane localization, transport characteristics, and substrate and inhibitor 
specificity. A number of the recently cloned transporters, such as the 
PAH/dicarboxylate exchanger OAT1, the anion/sulfate exchanger SAT1, the 
peptide transporters PEPT1 and PEPT2, and the nucleoside transporters CNT1 and 
CNT2, are key proteins in organic anion handling that possess the same 
characteristics as has been predicted from previous physiological studies. The role 
of other cloned transporters, such as MRP1, MRP2, OATP1, OAT-K1, and OAT-K2, 
is still poorly characterized, whereas the only information that is available on the 
homologs OAT2, OAT3, OATP3, and MRP3-6, is that they are expressed in the 
kidney, but their localization, and not to mention their function remain to be 
elucidated.
(available online at http://ajprenal.physiology.org/)
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Chapter One (Introduction)
Introduction
The human body is continuously exposed to a great variety of xenobiotics, via 
food, drugs, occupation and environment. Excretory organs such as kidney, liver 
and intestine defend the body against the potentially harmful effects of these 
compounds by biotransformation into less active metabolites and excretory 
transport processes. Most drugs and environmental toxicants are eventually 
excreted into the urine, either in the unchanged form or as biotransformation 
products. The mechanisms that contribute to their renal excretion are closely 
related to the physiological events occurring in the nephrons, i.e. filtration, 
secretion and reabsorption. Carrier-mediated transport of xenobiotics and their 
metabolites is confined to the proximal tubule, and separate carrier systems exist 
for the active secretion of organic anions and cations. Both systems are 
characterized by a high clearance capacity and tremendous diversity of substances 
accepted, probably resulting from multiple transporters with overlapping substrate 
specificities.
This review will focus on the molecular aspects of renal organic anion 
transporters. These systems play a critical role in the elimination of a large number 
of drugs (e.g. antibiotics, chemotherapeutics, diuretics, nonsteroidal anti­
inflammatory drugs, radiocontrast agents, cytostatics), drug metabolites (especially 
conjugation products with glutathione, glucuronide, glycine, sulfate, acetate), and 
toxicants and their metabolites (e.g. mycotoxins, herbicides, plasticizers, 
glutathione S-conjugates of polyhaloalkanes, polyhaloalkenes, hydroquinones, 
aminophenols), many of which are specifically harmful to the kidney. For a review 
on the molecular pharmacology of renal organic cation transporters the reader is 
referred to a recent comprehensive paper by Koepsell et al. [80]. The purpose of 
this paper is to give a concise review of the latest molecular information on 
organic anion transporters that contribute to the renal handling of xenobiotics and 
their metabolites. These transporters are depicted in Figure 1 and listed in Tables 1 
and 2. The systems involved in organic anion secretion can be functionally
14
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subdivided in the well characterized, sodium-dependent p-aminohippurate (PAH) 
system and a recently discovered sodium-independent system [108,109,147]. Both 
systems mediate two membrane translocation steps arranged in series: uptake from 
blood across the basolateral membrane of renal epithelial cells followed by efflux 
into urine across the apical membrane. While transported through the cytoplasm, 
substrates for both systems also accumulate in intracellular compartments. 
Furthermore, at the apical membrane several transport systems have been 
identified which are involved in reabsorption of anionic xenobiotics.
Recent discoveries on the molecular identity of some of the renal organic 
anion transporters (OAT1, SDCT2, SAT1, PEPT1, PEPT2, CNT1, CNT2) have 
confirmed the characteristics that have been predicted creatively by earlier 
functional studies performed in isolated membrane vesicles and proximal tubules. 
The same studies have indicated the existence of further anion transporters that 
have not yet been identified at the molecular level. For other recently cloned 
organic anion transporters information on their function (MRP1, MRP2, OATP1, 
OAT-K1, OAT-K2) and renal localization (OAT2, OAT3, MRP3-6) remains to be 
elucidated. Emphasis in this review is being placed on molecular characteristics, 
nephron and plasma membrane localization, transport properties, and substrate 
and inhibitor specificity of cloned renal organic anion transporters and homologs.
15
Table 1
Molecular characteristics o f organic anion transporters in the kidneya
Name Alternative
name
Species Acc. No. Chromosome
localization
Mrb
(kDa)
mRNA
(kb)
TM Tissue
Distribution
Nephron
Distribution
Membrane
Localization
References
OAT1 hPAHT/ human AF097490/AB009697/ 11q11.7 60 2.4 12 k PT BLM [59,105,150,152]
hROATI AF057039/AF104038
Oat1 ROAT1 rat AB004559/AF008221 60 2.4 12 k PT (S2) BLM [166,176,186,191]
Oat1 fROAT flounder Z97028 60 nd 12 nd nd nd [205]
Oat1 NKT/mOAT mouse U52842 19 60 2.5 11 k PT nd [89,103]
Oat2 NLT rat L27651 60 2.1 12 k, li nd nd [165,172]
OAT3 human AF097491 11q11.7 62 3.0 12 k nd nd [150]
Oat3 Roct mouse AF078869 19 62 2.1 12 k PT nd [13]
Oat3 rat AB017446 k, li, b, e nd nd [88]
Sat1 rat L23413 75 3.7 12 k, li, b, m PT (S1-S3) BLM [9,73]
MRP1 M RP human L05628 16p13.12-13 171 6.5 18 ubiquitous nd nd [20,39,213]
Mrp1 mouse AF022908 171 6.5 18 ubiquitous LH, CCD BLM [174,201,203]
MRP2 cMOAT/ human NM_000392/ 10q24 175 6.5 18 k, li, si, n nd nd [82,181]
cM RP U63970/ U49248/
X96395
Mrp2 rat L49379/ D86086/ 175 6.5 18 k, li, si PT (S1-S3) BBM [75]
X96393
Mrp2 rabbit Z49144 175 6.5 18 k, li, si PT (S1-S3) BBM [194], unpublished
MRP3 MOAT-D/ human Y17151/ AF104943 17q21.3 170 6.5 18 k(?), li, si, c, lu, nd BLM c [42,78,82,84,188]
cMOAT2 NM_003786/ p
AF085690/ AF009670
Mrp3 MLP2 rat AB010887/ AF072816 170 6.5 18 k, si, c, lu nd nd [57]
MRP4 MOAT-B human U83660/ AF071202 13q31-32 150 6.0 12 (k, lu, bl, gb)d nd nd [82]
ubiquitous6 [90]
MRP5 MOAT-C/ human U83661/ AF104942/ 3q27 160 nd 12 ubiquitous nd BLM [5,82,118,202]
SMRP/ AB005659/AB019002
pABC11 /AF146074
Mrp5 mouse AB019003 160 nd 12 nd nd nd unpublished
MRP6 MOAT-E human AF076622 16p13 165 6.0 18 k, li nd nd [6,83]
Mrp6 MLP1 rat AB010466/ U73038 165 6.0 18 k, li, du nd BLM c [57,107]
Mrp6 mouse AB028737 165 nd 18 nd nd nd unpublished
Name Alternative
name
Species Acc. No. Chromosome
localization
Mrb
(kDa)
mRNA
(kb)
TM Tissue
Distribution
Nephron
Distribution
Membrane
Localization
References
Oatpl Oatp rat L19031 nd 74 2.7 12 k, li, b, lu, m, c PT (S3) BBM [8,68]
Oatp3 rat AF041105 nd 74 2.8/3.9 12 k, r nd nd [1]
Oat-k1 rat D79981 nd 74 3.0 12 k PT (S3) BBM [117,158]
Oat-k2 rat AB012662 nd 55 2.5 8 k PT (S1-S3)/ CCD BBM [114]
CNT1 human U62968 15q25-26 71 3.4 14 k, si, li nd nd [153]
Cnt1 cNT1 rat U10279 71 3.0 14 k, si, li nd nd [38,60]
Cnt1 pig AF009673 71 nd 14 nd nd nd [137]
CNT2 hSPNT1 human U84392 15q15 71 4.5 14 ubiquitous nd nd [154,198]
Cnt2 SPNT rat U25055 71 3.5 14 k, si, li nd nd [18,38]
Cnt2 mouse AF079853 71 nd 14 nd nd nd unpublished
PEPT1 human AF043233/ U13173/ 13q33-34 78 3.3 12 k, si, li, pl nd nd [95]
U21936
PepT1 rat D50306/ D50664 78 3.0 12 k, si PT (S1-S2) BBM [126,159,169]
PepT1 mouse Y07561 78 nd 12 nd nd nd unpublished
PepT1 rabbit U06467/ U13707 78 2.9 12 k, si, li, b cortex nd [11,37]
PEPT2 human S78203 3q13.3-q21 78 4.2 12 k, b nd nd [151]
PepT2 rat D63149 78 4.0 12 k, b, lu PT (S3) BBM [160,169,197]
PepT2 rabbit U32507 78 4.8 12 k, b, lu, li nd nd [10]
“Abbreviations: (R)OAT: (renal) organic anion transporter; hPAHT: human PAH transporter; NKT: novel kidney transporter; NLT: novel liver transporter; Sat1 : sulfate anion 
transporter; MRP: multidrug resistance protein; cMOAT: canalicular multispecific organic anion transporter; cMRP: canalicular M RP; MLP: multidrug resistance protein-like 
protein; Oatp: organic anion transport polypeptide; Oat-k1/Oat-k2: kidney-specific organic anion transporter 1 and 2; CNT: concentrative nucleotide transprorter: PEPT: peptide 
transporter; TM: transmembrane-spanning domain; BLM: basolateral membrane; BBM : brush-border membrane; PT: proximal tubule; nd: not determined; k: kidney; li: liver; lu: 
lung; b: brain; si: small intestine; c: colon; t: testis; r: retina; pl: placenta; p: pancreas; n: nerve; du: duodenum; m: muscle; bl: bladder; gb: gallbladder; CCD: cortical collecting 
duct; LH: limb of Henle's loop 
bCalculated from the deduced amino acid sequence. 
cBased on localization in liver (baso)lateral membranes. 
dTissue distribution reported by Kool et al. [82].
'Tissue distribution reported by Lee et al. [90].
Table 2
Functional characteristics o f organic anion transporters in the kidneya b
Name transport
mechanism
Substrates (Km) 
unconjugated_______________ conjugated
Inhibitors (Ki) References
OAT 1
Oat1
human
rat
OA/
dicarboxylate
antiport
OA/
dicarboxylate
antiport
Oat2
Oat3
Sat1
rat
rat
nd
nd
rat OA/ sulfate
antiport
Mrp2 rat
PAH (5 uM)
PAH (14-70 uM); 
salicylate; MTX; cAMP; 
acetylsalicylate; 
indomethacin; folate; 
cGMP; PGE2; urate; a- 
KG; ochratoxin A
furosemide; indomethacin; 
probenecid; urate; a-KG; 
glutarate
naproxen (2 uM); ibuprofen 
(3.5 uM); salicylurate (11 uM); 
piroxicam (52 uM); salicylate 
(341 uM); acetylsalicylate (428 
uM); phenacetin (488 uM); 
paracetamol (2 mM); 
furosemide; indomethacin (10 
uM); probenecid; urate; a-KG; 
glutarate; MTX; PGE2; cAMP; 
cGMP
[59,105,150]
[3,166,176,
187,191]
MRP1 human primary active
(18 uM); salicylate (90 bumetanide; enalapril;
uM); acetylsalicylate cefoperazone; cholate
PAH (65 uM); BSP; probenecid; indocyanine
ochratoxin A (0.74 uM); green; bumetanide; piroxicam;
estrone-sulfate (2.3 uM); furosemide; AZT; DlDS
cimetidine
sulfate (320 uM); DIDS; oxalate; sulfate
oxalate
GSH; PAH LTC4 (0.1 uM); E2 1 7 KG (1.5 MK571 (0.6 uM); CsA (5 uM);
uM); DNP-SG (3.6 uM); PSC833 (27 uM); S-(decyl)-
bilirubin-glucuronide; GSSG glutathione (0.7uM); GS-DOX
(93 uM); AFB1-SG (0.2 uM); (60/120 nM); GS-DAU
PGA 1-SG; PGA2-SG (1 uM); (70/200 nM); probenecid
etoposide-glucuronide; S-
(ethacryn ic acid)-glutathione
[165]
[88]
[9,73]
[33,35,69,70, 
76,92, 98,99, 
101,145,149, 
210]
MRP2 human primary active GSH; MTX LTC4(1 uM); E217KG (7 uM); [24,34]
DNP-SG; PGA 1-SG; 
bilirubin-glucuronide; S- 
(ethacryn ic acid)-glutathione
GSH; MTX (100 uM); LTC4(1 uM); E217SG (7 uM); MK571; CsA; GSH (20 mM) [2,24,63,65,
folate; pravastatin (170 LTD4(1.5 uM); N-acetyl- LTE4 67,70, 79, 87,
uM); BSP (31 uM); Fluo- (5.2 uM); DNP-SG (0.1 8 uM); 106,113,130,
3 (4 uM); BQ123 (100 bilirubin-glucuronide; GSSG 134-136,142,
uM); BQ485 (7 uM); 
BQ518 (15 uM);
(111 uM); p-nitrophenyl- 
glucuronide (20 uM); a-
194, 206]
temocaprilat (100 uM); naphthyl-^-D-glucuronide;
cefpiramide; ceftriaxone E3040-glucuronide
Mrp2 rabbit GSH LTC4(1 uM); E217SG PAH; lucifer yellow;
fluorescein-methotrexate;
phenolphthalein-glucuronide;
CsA, probenecid
MRP3 human primary active 
Mrp3 rat
MRP4 human primary active 
MRP5 human primary active 
Mrp6 rat primary active
MTX
MTX
PMEA; AZTMP 
CMFDA; BCECF; FDA 
BQ123
DNP-SG
E217KG (70 uM); E3040- 
glucuronide
E3040-glucuronide;
a-naphthyl-j3-D-glucuronide;
MTX
dipyridamole
sulfinpyrazone
[192-194]
[84]
[58]
[164]
[118]
[1 0 7 ]
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Name transport Substrates (Km) Inhibitors (Ki) References
mechanism
unconjugated conjugated
Oatpl rat OA/GSH TC (27 uM); BSP (1.5 uM); LTC4 (0.27 j j M ); DNP-SG [32,41,64,71,
antiport aldosterone (15 nM); (408 ^ M); E217ßG (3 ^M); 72,94,138]
cortisol (13 nM); ouabain estrone-sulfate (4.5 >wM)
(17 mM); ochratoxin A
(17 uM); thyroxine;
triiodo-L-thyronine;
enalapril (214 uM);
temocrapilat (47 uM)
Oatp3 rat nd TC (18 uM); thyroxine (5 [1]
uM); triiodo-L-thyronine (7
uM)
Oat-k1 rat nd MTX (1 uM); folate MTX; BSP; probenecid; PAH; [116,158]
furosemide; valproate; DIDS;
TCA; ibuprofen; flufenamate;
phenylbutzone; indomethacin
(1 mM); ketoprofen (2 mM)
Oat-k2 rat nd TC (10 ywM); MTX; PGE2; MTX; BSP; probenecid; PAH; [114]
folate furosemide; valproate; DIDS;
TCA; levofloxacin;
indomethacin; testosteron;
dexamethasone; 17^-estradiol;
ouabain
CNT1 human nucleoside/ adenosine (15/26 uM); AZT; cytarabine; [36,60,153,
Cnt1 rat Na+ symport thymidine (13 uM); dideoxycytidine; floxidine; 207,208]
uridine (26/45); AZT (0.5 idoxuridine; thymidine;
mM); dideoxycytidine (0.5 cytidine; uridine
mM)
CNT2 human adenosine (8 uM); uridine formycin B, guanosine, [154,198]
nucleoside/ (40/80 uM); inosine (5 adenosine, uridine, inosine
Na+ symport uM)
Cnt2 rat [18,162]
adenosine (6 uM); inosine formycin B, guanosine,
(20 uM); uridine (20 uM); uridine, inosine, thymidine
cladribine, thymidine (13
uM)
PEPT1 human peptide/ H + glycylsarcosine (1.1 mM); ampicillin (50 mM); [4,31,43-45,
PepTI rat symport ALA (0.28 mM); amoxicillin (13 mM); 55,120,180,
PepTI rabbit ceftibuten (0.3 mM); cyclacillin (0.17 mM); 182,183,200]
cyclacillin (0.5 mM); cephalexin (5 mM); cefadroxil
cephalexin; cefixime; (2 mM); cephradine (9 mM);
cefadroxil; L-Val-ACV (5 cefdinir (12 mM); ceftibuten
mM); L-Val-AZT; L-dopa-L- (0.6 mM); cefixime (7 mM);
Phe; /brmy/-Met-Leu-Phe bestatin (0.5 mM); enalapril
(4.3 mM); captopril (9 mM); L-
Val-ACV (0.74 mM)
PEPT2 human peptide/ H + glycylsarcosine (0.11 ampicillin (0.67 mM); [31,43-45,183]
PepT2 rat symport mM); ALA (0.23 mM); amoxicillin (0.18 mM);
PepT2 rabbit cephalexin; bestatin; L- cyclacillin (27 >wM); cephalexin
Val-ACV (50 juM); cefadroxil (3 juM);
cephradine (47 uM); cefdinir
(20 mM); ceftibuten (1 mM);
cefixime (12 mM); bestatin (20
uM); L-Val-ACV (0.39 mM)
^Abbreviations: PAH: p-amminohippurate; OA: organic anion; a-KG: a-ketoglutarate; MTX: methotrexate; PGE2, prostaglandin E2; BSP: 
bromosulfophthalein; DIDS: 4,4'-diisothiocyanostilbene-2, 2'-disulfonic acid; LTC4: leukotriene C4; LTD4 : leukotriene D4; CsA: cyclosporin A; 
E217£G: estradiol-17£-D-glucuronide; DNP-SG: dinitrophenyl-glutathione; GSSG, oxidized glutathione; GSH: reduced glutathione; AFB1-SG, 5- 
(aflatoxin B 1)-glutathione; E3040-glucuronide: 6-hydroxy-5,7-dimethyl-2-methylamino-4-(3-pyridylmethyl)benzothiazole glucuronide; PMEA: 9-(2- 
phosphonylmethoxyethyl)adenine; AZTMP: azidothymidine monophosphate; CMFDA: 5-chloromethylfluorescein; FDA: fluorescein-diacetate; 
BCECF: 2', 7'-bis-(2-carboxyethyl)-5 (and-6)-carboxyfluorescein acetoxymethyl ester; TC: taurocholate; AZT: 3'-azido-3'-deoxythymidine; ALA: 
delta-aminolevulinic acid; L-Val-ACV: valacyclovir; PGA2-SG: 5-(prostaglandin A2)-glutathione; GS-DOX: 5-(doxorubicin)-glutathione; GS-DAU: 5- 
(daunorubicin)-glutathione; BQ123: cyclo-(Trp-Asp-Pro-Val-Leu); BQ485: perhydroazepino-N-carbonyl-(Leu-Trp-Trp); BQ518: cyclo-(Trp-Asp-Pro- 
Thg-Leu).
bSubstrates mentioned for some transporters are indicative but not complete.
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Fig. 1. Schematic model of organic anion transporters in renal proximal tubule. Uptake of organic 
anions (OA-) across the basolateral membrane is mediated by the classical sodium-dependent 
organic anion transport system, which includes a-ketoglutarate (a-KG2-)/OA- exchange via the 
organic anion transporter (OAT1) and sodium-ketoglutarate cotransport via the Na+/dicarboxylate 
cotransporter (SDCT2). A second sodium-independent uptake system for bulky OA- has recently 
been identified, but its molecular identity is unknown. Intracellular accumulation occurs for 
substrates of both transport systems in mitochondria and vesicles of unknown origin. The apical 
(brush-border) membrane contains various transport systems for efflux of OA- into the lumen or 
reabsorption from lumen into the cell. The multidrug resistance transporter, MRP2, mediates 
primary active luminal secretion. The organic anion transporting polypetide, OATP1, and the 
kidney-specific OAT-K1 and OAT-K2 might mediate facilitated OA- efflux but could also be 
involved in reabsorption via an exchange mechanism. PEPT1 and PEPT2 mediate luminal uptake of 
peptide drugs, whereas CNT1 and CNT2 are involved in reabsorption of nucleosides.
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Basolateral transport systems
Transport studies using isolated membrane vesicles and intact proximal tubules 
have identified and characterized the classical transport system for uptake of small 
organic anions across the basolateral membrane by using p-aminohippurate (PAH) 
or fluorescein as a model substrate [147]. These studies have established that 
uptake of PAH is a tertiary active process by indirect coupling to the Na+ gradient. 
This gradient, which is maintained by the Na+/K+ ATPase, drives 
Na+/dicarboxylate cotransport into the cell and enables uptake of PAH in 
exchange for a dicarboxylate ion. The PAH/dicarboxylate exchanger (Oat1) has 
been cloned from various species. Based on similarities with transport 
characteristics found in membrane vesicles, SDCT2 has been proposed as the 
basolateral Na+/dicarboxylate cotransporter [19]. a-Ketoglutarate is by far the most 
abundant potential dicarboxylate counterion within the proximal tubular cell, and 
it has been shown that PAH or fluorescein uptake in renal proximal tubules 
increases with increasing internal a-ketoglutarate concentration [17,146,199]. The 
activity of the Na+/dicarboxylate exchanger accounts for approximately 60% of 
organic anion uptake [199], whereas the remainder can be explained by 
intracellularly stored a-ketoglutarate [146]. Mitochondrial metabolism seems 
responsible for the generation of this dicarboxylate, and from liver studies it is 
known that the mitochondrial a-ketoglutarate concentration exceeds that in 
cytoplasm 3-6 times [170,173]. These findings imply that alterations in cellular 
metabolism may have a direct effect on the secretory function of kidney proximal 
tubules. Apart from the classical PAH transporter, an additional uptake system has 
been characterized by using the bulky organic anion fluorescein-methotrexate as a 
substrate [109]. Uptake of fluorescein-methotrexate is independent of Na+ and is 
not inhibited by PAH or the dicarboxylate ion glutarate. The molecular identity of 
this transporter, however, has not yet been established. Finally, a sulfate/anion 
exchanger has been characterized in basolateral membrane vesicles and cloned 
from rat [53,73,86,148]. This transporter exchanges sulfate for HCO 3" or oxalate in
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a Na+-independent manner. Whereas multiple substrates have been proposed for 
the PAH/dicarboxylate and the sulfate/anion exchanger based on inhibition 
experiments [189], there is yet no evidence that these compounds are substrates 
themselves.
Organic anion transporter Oat1 (PAH/dicarboxylate exchanger)
Various groups have cloned a PAH/dicarboxylate exchanger (Oat1) from rat and 
flounder by expression cloning in Xenopus laevis oocytes [166,176,191,205]. 
Furthermore, rat Oat1 sequences have enabled cloning of the human ortholog, 
OAT1 (86% identity to Oat1) [59,105,150,152]. Expression of rat Oat1 in Xenopus 
oocytes and human OAT1 in HeLa cells results in uptake of PAH, which is trans­
stimulated by glutarate and cis-inhibited by glutarate, a-ketoglutarate, probenecid 
and fluorescein [166,176,191,205]. These transport characteristics correspond well 
to those established for PAH in basolateral membrane vesicles [147]. The 
localization to the basolateral membrane of proximal tubules further supports that 
OAT1 and Oat1 represent the classical basolateral PAH/dicarboxylate exchanger 
[59,186]. Oat1 has a broad substrate specificity and Oat1-mediated PAH transport 
is inhibited by various nonsteroidal anti-inflammatory drugs confirming previous 
results on in situ perfused rat proximal tubules using PAH as a substrate 
[3,166,187,189]. The substrate specificity of human OAT1 is more narrow, since it 
does not transport methotrexate or prostaglandin E2 unlike rat Oat1 [105]. 
Transport of PAH by both Oat1 and OAT1 is inhibited by phorbol 12-myristate 13- 
acetate (PMA) and this inhibition is reversed by staurosporin, indicating that 
organic anion uptake is negatively correlated to protein kinase C (PKC) activity 
[105,191]. These results are in agreement with previous reports on PKC-mediated 
inhibition of organic anion uptake into the opossum kidney cell line OK and 
proximal tubules of rabbit, killifish and flounder by using PAH, fluorescein, or 
dichlorophenoxyacetate as a substrate [46,54,121,178]. Since the Na+/K+ ATPase, 
the putative basolateral Na+/dicarboxylate exchanger SDCT2, as well as
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Oat1/OAT1 have multiple PKC phosphorylation sites, it remains to be established 
whether PKC controls basolateral organic anion transport directly or indirectly.
Oat2 and Oat3/OAT3
Functional expression in Xenopus oocytes of a putative rat liver transporter, 
initially designated as NLT, revealed uptake of a-ketoglutarate, methotrexate, 
prostaglandin E2, acetylsalicylate, and PAH similar to rat Oat1 [165,172]. Since rat 
NLT also shows highest identity to rat Oat1 (42%), NLT has been renamed to Oat2 
[165]. In addition to liver, Oat2 is also expressed in kidney. Kusahara et al. have 
cloned a novel transporter (Oat3), which shares an identity of 49% and 39% with 
Oat1 and Oat2, respectively [88]. Oat3 is expressed in brain, kidney, liver and 
eye, and also mediates uptake of PAH and other organic anions. In contrast to 
Oat1, uptake of organic anions mediated by Oat2 and Oat3 is independent of Na+ 
and glutarate [3,88,165]. This indicates that the presence of a concentration 
gradient is sufficient for Oat2 and Oat3 to enable organic anion transport. It is at 
present not clear whether Oat2 and Oat3 mediate efflux and/or reabsorption of 
organic anions because membrane localization and nephron distribution are not 
yet established.
Race et al. recently reported the cloning of OAT1 and a kidney-specific 
homolog called OAT3 (84% identity to Oat3) [150]. Expression of OAT3 in 
Xenopus oocytes, however, did not result in uptake of PAH [150], suggesting that 
OAT3 is not the human ortholog of rat Oat3. Brady et al. have cloned a murine 
gene encoding a putative transporter (Roct) with highest identity to Oat3 (92%) 
and OAT3 (83%) [13]. Expression of murine Oat3/Roct is abundant in kidneys of 
wildtype mice but markedly reduced in kidneys of mice homozygous for the 
recessive osteosclerosis (oc) mutation [13]. Both the oc mutation as well as the 
murine oat3/roct gene have been mapped to chromosome 19, although no 
mutations have yet been identified in the oat3/roct gene of oc mice [13]. In a 
similar way, the OAT3 gene has been mapped closely to the region were human 
recessive osteopetrosis, a disease with a similar pathophysiology as osteosclerosis,
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has been mapped [13,56]. Further studies are required to elucidate the relation 
between these transporters and the phenotype of osteosclerosis and osteopetrosis.
Sulfate/anion exchanger Sat1
Expression cloning using Xenopus laevis oocytes has identified a sulfate/anion 
exchanger (Sat1) from rat kidney and liver [9,73]. In the kidney, Sat1 is located at 
the basolateral membrane of proximal tubules [73]. Expression of Sat1 in Sf9 cells 
results in uptake of sulfate and oxalate, which is cis-inhibited by oxalate and 
sulfate, respectively [73]. In addition, DIDS but not succinate inhibits Sat1- 
mediated sulfate uptake [9]. These transport characteristics are in close agreement 
to those found in proximal tubule basolateral membrane vesicles [53,86,148]. The 
cloning of Sat1 enables to answer the question whether the compounds proposed 
as substrates based on earlier inhibition studies are indeed transported by Sat1.
Multidrug resistance protein MRP1
The human multidrug resistance protein 1 (MRP1) is a member of the large family 
of ATP-binding cassette (ABC) proteins and functions as an ATP-dependent 
transporter of anionic conjugates, such as leukotriene C4, S-(dinitrophenyl)- 
glutathione, estradiol-17£-D-glucuronide, and etoposide-glucuronide [93,98, 
99,132]. MRP1 is expressed in various tissues, including blood cells [39,213]. 
Mice homozygous for a disrupted mrp1 gene (mrp1 -/-) have an impaired response 
to an inflammatory stimulus, probably as a consequence of decreased leukotriene 
C4 secretion from leukocytes [201]. Murine Mrp1 is localized to the basolateral 
membrane of various epithelial cells and human MRP1 is routed to the basolateral 
membrane when expressed in the epithelial cell lines LLC-PK1 and MDCKII 
[33,35,203]. In murine kidney, Mrp1 is expressed at the basolateral membrane of 
cells of Henle's loop and the cortical collecting duct [144,203]. Although 
previously suggested [155], Mrp1 does not appear to be expressed in the proximal 
tubule [144,203].
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Human MRP1 is frequently overexpressed in various multidrug resistant (MDR) 
cancer cell lines selected with cationic (chemotherapeutic) drugs [21]. Transfection 
of a human MRP1 cDNA into drug-sensitive cells results in resistance to various 
cationic drugs, such as vincristine, doxorubicin, and etoposide [22,50,211]. In 
addition, mrp1 -/- mice are hypersensitive to such drugs [104,201,203]. Since 
administration of etoposide to mrp1 -/- mice results in polyurea, MRP1 might 
protect distal parts of the nephron, which are exposed to high concentrations of 
drugs as a result of water reabsorption [203].
MRP3, MRP4, MRP5 and MRP6
Searching of the GenBank database EST sequences enabled identification of four 
additional human MRP-like genes alongside MRP1 and MRP2 (see apical organic 
anion transport systems). Expression of MRP3 [5,78,82,85,188], MRP4 [82,164], 
MRP5 [5,82,118], and MRP6 [83] mRNA has been found in various tissues, 
including kidney. However, Lee et al. [90] did not find expression of MRP4 in the 
kidney.
The subcellular localization and nephron distribution of these novel MRPs in 
the kidney is at present unknown. However, immunohistochemistry on liver 
sections has demonstrated the presence of human MRP3 at the basolateral 
membrane of intrahepatic bile-duct epithelial cells (cholangiocytes) and 
hepatocytes, whereas rat Mrp6 has been located specifically to the hepatocyte 
lateral membrane [84,85,107]. Similarly, human MRP5 is confined to the 
basolateral membrane of various epithelial cells [202]. Transport characteristics of 
several of these novel MRPs have been reported recently. MDCKII cells 
overexpressing human MRP3 show increased efflux of S-(dinitrophenyl)- 
glutathione across the basolateral membrane compared to the parental cells [84]. 
Furthermore, MRP3 confers resistance to the chemotherapeutic drugs etoposide, 
teniposide, and methotrexate [84]. In the cell line HepG2, endogenously 
expressed MRP3 mRNA is induced by phenobarbital [78]. Membrane vesicles 
from LLC-PK1 cells transfected with a rat mrp3 cDNA exhibit ATP-dependent
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uptake of estradiol-175-D-glucuronide and E3040-glucuronide, but not leukotriene 
C4 or S-(dinitrophenyl)-glutathione [58]. In a T-lymphoid cell line, overexpression 
of human MRP4 mRNA and MRP4 protein was found to be correlated with 
enhanced ATP-dependent efflux of nucleoside monophosphate analogs [164]. 
Expression in HEK293 cells of human MRP5 conjugated to green fluorescent 
protein results in reduced labeling of some fluorescent anionic agents [118]. In a 
preliminary report, rat Mrp6 was shown to mediate ATP-dependent transport of the 
anionic cyclopentapeptide endothelin antagonist BQ123 [107]. Further studies are 
required to determine the transport characteristics of these MRPs and to define 
their role in the kidney.
Intracellular disposition of anionic drugs
Anionic drugs accumulate in proximal tubules as a result of secretory transport, 
possibly in combination with reabsorption. The degree of accumulation is 
determined by the extent at which anionic drugs are actively transported across 
the basolateral membrane, their intracellular disposition and ease at which they 
can be transported across the brush-border membrane into the tubular lumen.
In vitro studies in isolated proximal tubular cells have indicated that, at low 
medium concentrations, PAH and fluorescein accumulate intracellularly at 
concentrations 3-5 times the medium concentration [112]. Fluorescein 
accumulation in proximal tubular cells during secretory transport has recently 
been confirmed in rat kidney in vivo [1 2 ]. Confocal microscopic images of rat 
proximal tubular cells showed compartmentation of fluorescein in subcellular 
organelles. In particular mitochondria appear to concentrate fluorescein via the 
metabolite anion transporters in the inner membrane [110,112,184]. On the other 
hand, Miller et al. suggested nocodazole-sensitive vesicular compartmentation in 
crab urinary bladder [122,124,125]. Nocodazole disrupts the Golgi apparatus and 
subsequently microtubules, which are involved in the movement of transporting
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vesicles thorough the cells [14]. This indicates that at least two different 
compartments may be involved in the intracellular sequestration of organic anions. 
The involvement of microtubules in vesicular compartmentation suggests a role in 
transcellular transport and/or secretion. Another possibility is that endosomal 
membranes play a role in the rapid and directed trafficking of transporters to and 
from the apical membrane.
Hardly any research is done on transcellular transport of organic anions in the 
renal proximal tubule. Two decades ago the presence of anion binding proteins 
were shown, of which ligandin or glutathione S-transferase B is the most important 
[16,96,167]. Several anionic drugs interact with these binding proteins, suggesting 
that they play a role in the reduction of free cytoplasmic drug concentrations and 
maybe in transcellular drug trafficking [49,77,96]. Binding to glutathione S- 
transferase, however, appeared not to be a determinant for the rate of luminal 
secretion [143]. Unfortunately, more recent data on the role of binding proteins is 
not available.
Finally, metabolism may be an important intracellular event associated with 
renal anionic xenobiotic disposition. The biotransformation pathways reported 
involve oxidative, reductive and hydrolytic reactions (phase I reactions), and 
conjugation to glucuronide, sulfate or reduced glutathione (phase II reactions) 
[48,97,102,129]. Microsomal oxidation through cytochrome P450-dependent 
mechanisms takes place predominantly in kidney proximal tubules [102]. 
Glucuronide conjugates are formed through the enzymatic activity of UDP- 
glucuronosyltransferase, of which various isozymes have been identified in the 
kidney. Renal sulfate conjugation is catalyzed by sulfotransferase, but is 
quantitatively less than glucuronide conjugation [97,102]. Conjugation to reduced 
glutathione (GSH) is catalyzed by GSH-transferase, and the conjugates may 
subsequently be transformed into cysteine conjugates and mercapturic acid by y- 
glutamyltranspeptidase and N-acetyltransferase, respectively [23]. The enzymes 
involved in glucuronide, sulfate or GSH conjugation are not uniformly distributed 
in the kidney, but show the highest activity in the proximal tubule
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[62,97,102,209]. The different enzymes involved in GSH-derived 
biotransformation reactions (y-glutamyltranspeptidase and N-acetyltransferase) 
express a high activity predominantly in S3 segments of the proximal tubule [61]. 
Biotransformation reactions are primarily detoxification mechanisms, although 
toxic metabolites may be produced as well (e.g. acetaminophen [29,133], 
halogenated alkanes [133], cisplatin [26,168], cyclosporin A [7], ochratoxin A 
[30,47]).
Apical transport systems
Much of the transport systems for organic anions in the brush-border membrane of 
the proximal tubule have initially been characterized in membrane vesicle studies 
[147]. Small organic anions, such as PAH and fluorescein, are excreted via a 
facilitated transporter driven by the potential difference of about -70 mV from cell 
to lumen. In addition, an anion exchange mechanism has been identied in some 
species, such as dog, rat and human but not in rabbit. Neither of these efflux 
systems have been cloned. Based on inhibition experiments in in situ perfused 
proximal tubules, Ullrich et al. suggested multiple substrates for these organic 
anion transporters [190]. Studies with intact killifish proximal tubules have 
indicated two efflux pathways for organic anions [108,109,123]. One pathway 
mediates Na+-dependent efflux of small organic anions, independent of the 
membrane potential [109,123]. Bulky organic anions, such as fluorescein- 
methotrexate and lucifer yellow, are excreted via an energy-dependent efflux 
system, which is insensitive to PAH and depletion of Na+' but inhibited by 
leukotriene C4 and S-(dinitrophenyl)-glutathione [108,109]. A likely candidate for 
this transport system is the apical ATP-dependent anionic conjugate transporter 
Mrp2. Apart from efflux mechanisms, the brush border membrane also contains 
transport systems for reabsorption of compounds from primary urine. Small 
anionic peptides are actively taken up via H+/peptide cotransporters by coupling
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to the H+-gradient [27]. In addition, anionic nucleosides are actively taken up by 
Na+/nucleoside cotransporters by coupling to the Na+-gradient [40,51,204].
MRP2
The multidrug resistance protein 2 (MRP2) is an ATP-dependent organic anion 
transporter with highest identity to MRP1 (48%) and MRP3 (46%). MRP2, also 
described as canalicular multispecific organic anion transporter (cMOAT), is 
expressed at the apical membrane of hepatocytes [15,140], renal proximal tubules 
[163], and small intestinal villi (see chapter 3). In liver, MRP2 plays an important 
role in the biliary excretion of multiple conjugated and unconjugated organic 
anions across the canalicular (apical) membrane. Defective function of Mrp2, as 
observed in the two mutant rat strains EHBR and GY/TR", results in 
hyperbilirubinemia [15,66,140]. Furthermore, in patients with Dubin-Johnson 
syndrome, a rare autosomal recessive liver disorder with a similar phenotype as 
the mutant rats, mutations have been identified in the MRP2 gene [74,141,196].
The transport characteristics of Mrp2 have been investigated extensively in 
comparative studies with wildtype and Mrp2-deficient rats using perfused liver, 
and isolated canalicular membrane vesicles or hepatocytes [136,175]. In contrast 
to liver canalicular membrane vesicles, membrane vesicles from the proximal 
tubule brush-border membrane are unsuitable for characterizing Mrp2-mediated 
transport. Since these vesicles are exclusively orientated rightside-out, the ATP- 
binding site is inaccessible for extravesicular ATP [52]. Studies with killifish renal 
proximal tubules have indicated the presence of an MRP-like transporter involved 
in the energy-dependent and leukotriene C4-sensitive efflux of fluorescein- 
methotrexate and lucifer yellow [108,109]. Immunohistochemistry with a 
polyclonal antibody raised against rabbit Mrp2 has located a killifish ortholog to 
the brush-border membrane, which further supports this hypothesis [111]. 
Functional evidence exists for the presence of apical transporters other than Mrp2 
involved in renal excretion of organic anions. For example, efflux of lucifer yellow 
from killifish proximal tubules is only partly inhibited by the Mrp2 substrates
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leukotriene C4 and S-(dinitrophenyl)-glutathione [108]. Also, renal clearance of the 
Mrp2 substrates a-naphtyl-^-D-glucuronide [28], E3040-glucuronide [179], 
cefpiramide [130], the quinolone HSR-903 [131], and lucifer yellow (R. 
Masereeuw and F.G.M. Russel, unpublished) is not impaired in Mrp2-deficient 
rats.
Like MRP1 and MRP3, human MRP2 not only transports anionic conjugates 
but also confers resistance to various cationic chemotherapeutic drugs [24,81]. 
Studies with membrane vesicles from cells expressing human MRP1 have 
indicated that uptake of cationic drugs, such as vincristine, daunorubicin, and 
aflatoxin B1 only occurs in the presence of physiological concentrations of GSH 
[69,99-101]. A similar GSH dependency of ATP-dependent vinblastine transport 
has been shown for rabbit Mrp2 (see chapter 4). This explains the finding that 
MRP1- and MRP2-mediated drug resistance is reversed by an inhibitor of GSH 
synthesis [24,195,212]. For human MRP1, the mechanism involved in GSH- 
stimulated ATP-dependent transport of vincristine has been identified as a 
GSH/vincristine cotransport mechanism [100]. Daunorubicin and etoposide, 
unlike vincristine, did not stimulate GSH transport indicating the involvement of a 
mechanism different from cotransport [100]. Recent studies have shown that MRP2 
[142], like MRP1 [142,212] and MRP5 [202] but not MRP3 [84], transports GSH 
itself.
Regulation of Mrp2-mediated transport has been investigated in isolated rat 
hepatocytes and killifish renal proximal tubules, however, results in these tissues 
are at variance. Both cAMP and PKC stimulated Mrp2-mediated efflux of an 
anionic conjugate across the hepatocyte apical membrane [156,157]. At least for 
the effect of cAMP, it has been shown to be a result of stimulated sorting of Mrp2 
containing vesicles to the apical membrane [157]. In the killifish proximal tubule, 
efflux of fluorescein-methotrexate is negatively correlated with PKC activity [111]. 
Activation of the signal transduction pathway occurs by binding of endothelin-1 to 
the B-type receptor [111]. Since endothelins are involved in many processes in the 
kidney, this suggests a specific regulatory pathway for renal Mrp2.
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Organic anion transport polypeptides Oatp1 and Oatp3
The organic anion-transporting polypeptide 1 (Oatp1) is a Na+- and ATP- 
independent transporter originally cloned from rat liver [6 8 ]. Oatp1 is localized to 
the basolateral membrane of hepatocytes where it plays a major role in uptake of a 
variety of anionic, neutral and cationic compounds from the blood [119]. In 
contrast, Oatp1 is located at the apical membrane of S3 proximal tubules [8 ]. 
Studies with transiently transfected HeLa cells have indicated that Oatp1 mediates 
uptake of taurocholate in exchange for HCO 3" [161]. In addition, uptake of 
taurocholate by Oatp1 expressed in Xenopus oocytes is accompanied by efflux of 
GSH [94]. As an anion/GSH exchanger, Oatp1 might mediate reabsorption of 
organic anions rather than efflux in the kidney. In this respect, reabsorption of 
ochratoxin A in proximal tubules is inhibited by bromosulfophthalein, which 
suggests the involvement of Oatp1 as both compounds have been identified as 
substrates [25,32]. On the other hand, since Oatp1 transports various anionic 
conjugates it might function as an efflux transporter, representing the transport 
mechanism maintained in kidneys of Mrp2-deficient rats. Abe et al. reported the 
cloning of an Oatp1-homolog, called Oatp3 (80 and 82% identity to Oatp1 and 
Oatp2, respectively) [1]. Oatp3 is highly expressed in kidney and mediates 
transport of thyroid hormones and taurocholate like Oatp1 and Oatp2  [1,41]. 
However, no data are yet available on the nephron distribution and membrane 
localization of Oatp3.
Organic anion transporters Oat-k1 and Oat-k2
Oat-k1 and Oat-k2 are kidney-specific Na+- and ATP-independent organic anion 
transporters with highest identity to Oatp1 (72% and 65%, respectively) [114,158]. 
Both transporters are confined to the brush-border membrane of proximal tubular 
cells [114,117]. Oat-k1 and Oat-k2 mediate transport of methotrexate and folate, 
whereas Oat-k2 also transports prostaglandin E2 and taurocholate [114,158]. 
Additional studies are required to elucidate whether Oat-k1 and Oat-k2 mediate 
efflux or reabsorption of organic anions. However, Oat-k1 expressed in MDCK
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cells transports methotrexate across the apical membrane in both directions [115]. 
Similarly, Oat-k2 transports taurocholate bidirectionally across the apical 
membrane upon expression in MDCK cells [114]. In a recent study, Oat-k1 was 
proposed as the ochratoxin A reabsorption pathway in proximal tubules based on 
the inhibitory effect of bromosulfophthalein [25]. Whereas bromosulfophthalein 
indeed inhibits Oat-k1 mediated transport [115,158], it also inhibits Oat-k2 
mediated transport [114]. Furthermore, there is no evidence to suggest that 
ochratoxin A is a substrate of either of these transporters. In this respect, various 
organic anions (i.e. nonsteroidal anti-inflammatory drugs, PAH, digoxin, 
probenecid), bile acid analogs, and steroids are potent inhibitors but no substrates 
of Oat-k1 and Oat-k2 [114-116,158]. Several of these drugs can accumulate to 
high concentrations in the proximal tubule, suggesting that under these conditions 
both transporters are inhibited.
Na+/nucleoside cotransporters CNT1 and CNT2
The concentrative nucleoside transporters CNT1 and CNT2 are involved in Na+- 
dependent transport of endogenous nucleosides and various synthetic (anionic) 
nucleosides, which are of clinical importance for their use in the treatment of 
cancer and viral infections [139]. CNT1 (N2 subtype or cit) is selective for 
pyrimidines whereas CNT2 (N1 subtype or cif) favors transport of purines, 
although uridine and adenosine are transported by both proteins 
[18,36,60,153,154,162,198,207,208]. Structural features markedly distinguishes 
rat Cnt2 from human CNT2, moreover, Cnt2 transports thymidine in contrast to 
CNT2 [18,154,198]. Northern blotting and reverse transcriptase polymerase chain 
reaction have identified expression of human CNT1 and CNT2 mRNA in the 
kidney [153,154,198]. Although their membrane localization has not been 
established by immunohistochemistry, Na+/nucleoside cotransport into cells 
overexpressing CNT1 or CNT2 resemble transport characteristics found in brush- 
border membrane vesicles [40,51,204]. This indicates that CNT1 and CNT2
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mediate Na+/nucleoside cotransport across the brush-border membrane into the 
proximal tubule.
H+/peptide cotransporters PEPT1 and PEPT2
Peptide transporters are involved in H+-dependent transport of small peptides and 
various peptide-like compounds such as anticancer drugs (bestatin, delta- 
aminovulinic acid), prodrugs (L-dopa-L-Phe, L-Val-AZT), inhibitors of angiotensin 
converting enzyme ACE (captopril, enalapril), and various anionic S-lactam 
antibiotics such as cephalosporins (cephalexin, cepharadine, cefadroxil, cefdinir) 
and penicillins (cyclacillin, ampicillin) [27,91]. Two peptide transporters have 
been cloned, i.e. a low-affinity transporter from intestine (PEPT1) and a high- 
affinity transporter from kidney (PEPT2) [27,91]. Immunohistochemistry has 
located PEPT2 to the proximal tubule brush-border membrane and characteristics 
of H+/peptide cotransport into various cell types expressing PEPT2 resemble 
transport characteristics found in brush-border membrane vesicles 
[10,127,128,151,169,171,177,185]. This indicates that PEPT2 mediates 
H+/peptide cotransport from the primary urine into the proximal tubule [27,169]. 
PEPT1 has also been located to the brush-border membrane but is difficult to 
characterize in membrane vesicles due to its relatively low expression and the 
interference of substrates with PEPT2 [27]. However, the ACE inhibitors enalapril 
and captopril are not transported by PEPT2, and these drugs have recently been 
used to characterize PEPT1-mediated transport in kidney [182].
Conclusive remarks
The past few years have witnessed great advances in our understanding of the 
molecular pharmacology of renal organic anion transport. Considerable progress 
has been made in cloning key proteins involved in the transport of anionic 
xenobiotics and metabolites and the list of cloned organic anion transporters is 
steadily growing. The challenge of future work will be to integrate this information
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with (patho)physiological, pharmacological and toxicological investigations at the 
cellular and organ level. There is still a large gap in our knowledge about the 
relative contribution of individual transporters to the membrane steps involved in 
tubular secretion of specific anionic substrates. More detailed knowledge of the 
cloned carrier proteins in expression systems and the availability of specific 
antibodies will allow more fundamental insight into membrane translocation at the 
molecular level, as well as participation in overall transepithelial secretion. This 
will also facilitate the research on the interaction of cellular messengers with the 
carrier proteins and the way these transporters are synthesized and targeted to 
specific membrane sites in the normal and diseased kidney. An important 
approach to study the in vivo function of transporters and their mutual interaction 
is to develop and characterize (multiple) null mutants of the genes encoding these 
proteins. Finally, it has become increasingly clear that intracellular disposition is 
an important step in the active secretion of anionic xenobiotics. How these 
processes interact with the membrane transport mechanisms to produce secretion 
and at what level and to what extent they are regulated will be important 
questions to answer.
A detailed knowledge of the renal mechanisms that govern intracellular 
distribution and membrane transport of xenobiotics in the kidney, is essential for 
the development of clinically useful drugs and will advance our understanding of 
the molecular, cellular and clinical basis of renal drug clearance, drug-drug 
interactions, drug targeting to the kidney and xenobiotic-induced nephropathy.
Aim and Outline of this Thesis
In 1996, at the department of Cell Physiology (University of Nijmegen), a novel 
homolog of MRP1 was cloned from a rabbit ileum cDNA library (van Kuijck et al. 
1996, Proc. Natl. Acad. Sci. 93, 5401). At the same time, Mrp2 was cloned from 
rat by three collaborative groups in Amsterdam (Paulusma et al., 1996, Science 
271, 1126). Comparison of the tissue distribution and the nucleotide sequence
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suggested that our clone is the rabbit ortholog of rat Mrp2. In this thesis, we 
functionally expressed rabbit Mrp2 in Sf9 cells to characterize its transport 
properties and to use this model system to identify putative substrates, with 
emphasis on compounds that are excreted by the kidney. In chapter 2, we 
describe the expression of rabbit Mrp2 in Spodoptera frugiperda (Sf9) cells and 
show Mrp2-mediated uptake of tracer substrates in isolated membrane vesicles. 
We investigated the immunolocalization of Mrp2 in rabbit small intestine, liver 
and kidney (chapter 3). In chapter 4, the mechanisms and interaction of 
vinblastine and GSH transport by Mrp2 were studied. In chapter 5, we investigated 
whether Mrp2 transports PAH in view of its putative role as renal organic anion 
transporter. In chapter 6, the results are summarized and a general discussion with 
future perspectives is given.
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Summary
The multidrug resistance protein Mrp2 is expressed in liver, kidney and small 
intestine and mediates ATP-dependent transport of conjugated organic anions 
across the apical membrane of epithelial cells. We recently cloned a rabbit cDNA 
encoding a protein that on basis of highest amino acid homology and similar tissue 
distribution was considered to be the rabbit homolog of rat Mrp2. To investigate 
whether rabbit Mrp2 mediates ATP-dependent transport similar to rat Mrp2, we 
expressed rabbit Mrp2 in Spodoptera frugiperda (Sf9) cells using recombinant 
baculovirus. Mrp2 was expressed as an underglycosylated protein in Sf9 cells and 
to a higher level compared with rabbit liver and renal proximal tubules. Both 
17ß-estradiol-17-ß-D-glucuronide ([3H]E2i 7 ßG, 50 nM) and [3H]leukotriene C4 (3 
nM) were taken up by Sf9-Mrp2 membrane vesicles in an ATP-dependent fashion. 
Uptake of [3H]E2i 7 ßG was dependent on the osmolarity of the medium and 
saturable for ATP (Km = 623 ^M). Leukotriene C4, MK571, phenolphthalein 
glucuronide, and fluorescein-methotrexate were good inhibitors of [3H]E2i7ßG 
transport. The inhibitory potency of cyclosporin A and methotrexate was 
moderate, whereas fluorescein, a-naphthyl-ß-D-glucuronide and p-nitrophenyl-ß- 
D-glucuronide did not inhibit transport. In conclusion, we show direct ATP- 
dependent transport by recombinant rabbit Mrp2 and provide new data on Mrp2 
inhibitor specificity.
(available online at http://molpharm.aspetjournals.org)
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Introduction
Elimination of endogenous waste products and xenobiotics from the body is 
mediated by renal and hepatic transport pathways. Excretion of anionic conjugates 
across liver canalicular (apical) membranes into bile is mediated by the multidrug 
resistance protein MRP2 [26]. Initially, this transporter was named cMOAT and 
characterized by using natural mutant strains of Wistar (TR-) and Sprague-Dawley 
(EHBR) rats [26]. Recently, cloning of rat Mrp2 revealed that the impaired 
conjugate transport in canalicular membranes of these rats is caused by a 
premature termination of the mrp2 gene product [11,27]. Similarly, a mutation 
leading to a truncated MRP2 was identified in a patient with Dubin-Johnson 
syndrome, a disease that resembles the TR- phenotype [28].
Database analysis revealed that rat Mrp2 is strongly related to the human 
multidrug resistance protein MRP1, a member of the superfamily of ABC proteins 
[3,11,27]. Originally, MRP1 was identified due to its overexpression in a multidrug 
resistant cell line and its ability to confer resistance to chemotherapeutic drugs 
[21]. Using isolated membrane vesicles from MRP7-transfected cells, it has been 
shown that MRP1 is also capable of transporting anionic conjugates in an ATP- 
dependent manner. Although MRP1 and MRP2 share substrate specificity, these 
transporters show differences in their tissue distribution. MRP1 is expressed, 
predominantly intracellularly, in numerous tissues such as lung, heart, and kidney 
[7]. In contrast, MRP2 was detected in small intestine and apical (canalicular) 
membranes of hepatocytes and cells of renal proximal tubules [3,27,33].
W e cloned a rabbit cDNA encoding an ABC-transporter that on basis of similar 
tissue distribution and highest amino acid homology was considered to be the 
rabbit homolog of rat Mrp2 [37,38]. On injection of its cRNAs in Xenopus laevis 
oocytes, we observed in a few cases a cAMP-dependent chloride conductance 
[38]. To investigate whether rabbit Mrp2 functions as an ATP-dependent organic 
anion transporter similar to rat Mrp2, we expressed rabbit Mrp2 in Sf9 cells using 
recombinant baculovirus and studied uptake of the anionic conjugates E217SG and
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LTC4 into isolated membrane vesicles. In addition, the effect of various inhibitors 
on Mrp2-mediated [3H]E217£G transport was investigated.
Experimental procedures
Materials. [14,15,19,20-3H]LTC4 (165 Ci/mmol) and [6,7-3H]E217GG (55 Ci/mmol) were 
purchased from NEN Life Science Products (Hoofddorp, The Netherlands). ATP, 5'-AMP, 
LTC4 , E2 1 7 GG, methotrexate (MTX), cyclosporin A (CsA), a-naphthyl-G-D-glucuronide, 
phenolphthalein glucuronide, and p-nitrophenyl-G-D- glucuronide were purchased from 
Sigma (Zwijndrecht, The Netherlands). FL-MTX and FL were purchased from Molecular 
Probes (Leiden, The Netherlands). Creatine phosphate and creatine kinase were 
purchased from Boehringer Mannheim (Almere, The Netherlands). CELLFECTIN and 
competent DH10BAC Escherichia coli cells were purchased from Life Technologies 
(Breda, The Netherlands). PNGase F was purchased from New England Biolabs 
(Westburg, Leiden, The Netherlands). MK571 was a generous gift of Dr. A. W . Ford­
Hutchinson (Merck Frosst, Center for Therapeutic Research, Quebec, Canada).
Preparation of antibodies. Rabbit polyclonal antibodies were directed against two different 
epitopes of rabbit Mrp2 [38]. Antiserum k78mrp2 was obtained by immunizing rabbits 
with a glutathione S-transferase fusion protein containing the 159 carboxyl-terminal amino 
acids (1405-1564) of Mrp2. Antiserum k51mrp2 was obtained by immunizing rabbits with 
a synthetic peptide (FQKRQQKKSQKNSRLQGL) corresponding to amino acids 257-274 
of Mrp2 coupled to keyhole limpet haemocyanin. Rabbits were immunized with 400 ^g 
of either the fusion protein or the synthetic peptide mixed with Freund's complete 
adjuvants. At 3-week intervals after priming, rabbits were boosted with 200 ^g of proteins 
supplemented with incomplete adjuvants. Test bleedings were checked for the presence 
of Mrp2-specific antibodies using enzyme-linked immunosorbent assay.
Expression construct. The vector pFASTBAC1 (Life Technologies) contains an expression 
cassette that consists of a polyhedrin promoter, a multiple cloning site and an SV40 
poly(A)+ signal inserted between the left and right arms of the bacterial transposon Tn7. 
Cloning of a rabbit mrp2 cDNA into pFASTBAC1 was accomplished in two steps: (1) from
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the pBluescript KS+ construct pBSmrp2, which contains the entire rabbit mrp2 coding 
sequence (nucleotides 347-5038) [38], a 2.7 kb XbaI/PstI fragment (nucleotides 2690­
5407) was cloned into the XbaI and PstI sites of the multiple cloning site of pFASTBAC1 to 
create pFASTBAC-m1; and (2) to minimize the 5'-untranslated region, the 5' coding 
sequence of rabbit Mrp2 was amplified by polymerase chain reaction using the forward 
primer Mrp2-F1 (5'-ATGCTGGATAAGTTCTGCAAC-3'; nucleotides 347-368), which 
contains the ATG start codon (underlined), and the reverse primer Mrp2-R1 
(5'-GCAGGAGTAGGCCAGATTAG-3'; nucleotides 844-824). The resulting polymerase 
chain reaction product of 498 bp was cloned into the SmaI site of pBluescript KS + and its 
sequence was verified by dideoxy sequence analysis [32]. From this construct, a 
StyI/HincII fragment was removed and replaced by a StyI/EcoRV fragment (nucleotides 
480-3007) from pBSmrp2. Next, a 2.5 kb BamHI fragment of this construct, containing the 
5'-region of mrp2 (nucleotides 347-2868), was cloned into the BamHI site of 
pFASTBAC1-m1 and its orientation was determined. The selected construct, designated 
pFBmrp2, contains a full-length rabbit mrp2 cDNA with the ATG start codon immediately 
downstream of the polyhedrin promoter.
Production of recombinant baculovirus and viral infection. Baculovirus encoding rabbit 
Mrp2 was generated using the Bac-to-Bac baculovirus expressing-system (Life 
Technologies). Competent DH10BAC E. coli cells harboring a baculovirus shuttle vector 
(bacmid) with a Tn7 attachment site were transformed with the pFBmrp2 construct. On 
transposition between the Tn7 sites, recombinant bacmids were selected and isolated 
according to the manufacturer. Subsequently, insect Sf9 cells were transfected with 
recombinant bacmids using CELLFECTIN reagent. After 3 days, culture medium was 
collected and used to infect fresh Sf9 cells. Four days after infection, stocks of amplified 
virus were made. Sf9 cells (106/ ml) were grown as 100 ml suspension cultures and 
infected at a multiplicity of infection (MOI) of 1-5 with recombinant baculovirus encoding 
Mrp2. For control experiments, Sf9 cells were infected with recombinant baculovirus 
encoding G-glucuronidase (Life Technologies) or the G-subunit of H+/K+ ATPase [16]. 
Three days after infection, membrane fractions were isolated (see below).
Isolation of membrane fractions. Crude membrane fractions and membrane vesicles from 
infected Sf9 cells were isolated as described by Leier et al. [19] with modifications. Briefly, 
cells were collected and resuspended in hypotonic buffer (0.5 mM sodium phosphate, 0.1
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mM EDTA, pH 7.0) supplemented with protease inhibitors (2 mM phenylmethylsulfonyl 
fluoride, 5 ^g/ml aprotinin, 5 ^g/ml leupeptin, 1 mM pepstatin). Cells were stirred gently 
on ice for 90 min and the resulting lysate was centrifuged at 100,000 x g for 40 min at 4 
°C. The pellet of crude membranes was resuspended in TS-buffer (10 mM Tris-Hepes, 250 
mM sucrose pH 7.4) using a Potter homogenizer and the homogenate was centrifuged at
12,000 x g for 10 min at 4 °C. The postnuclear supernatant was centrifuged at 100,000 x g 
for 40 min at 4 °C  and the pellet obtained was resuspended in TS-buffer with a tight-fitting 
Dounce (type B) homogenizer. The suspension was layered over 38% sucrose in 5 mM 
Hepes/KOH, pH 7.4, and centrifuged at 100,000 x g for 2 hr at 4 °C. The interphase was 
collected and homogenized on ice with a tight-fitting Dounce (type B) homogenizer and 
the suspension was centrifuged at 100,000 x g for 40 min at 4 °C. The resulting pellet was 
resuspended in TS-buffer and passed through a 27-gauge needle for 30 times. Membrane 
vesicles were frozen and stored at -80 °C  until use. Sidedness of membrane vesicles was 
assessed by measuring 5'-nucleotidase activity [6], and it was determined that ~65%  of 
the vesicles were orientated inside-out. Rabbit liver and kidney were excised and renal 
proximal tubular cells were isolated by immunodissection as described previously [30]. 
Crude membrane fractions were isolated as described previously [23]. Briefly, liver, 
kidney, and renal proximal tubular cells were homogenized in buffer A (300 mM sucrose, 
25 mM imidazole, 1 mM EDTA, pH 7.2) supplemented with protease inhibitors as 
described above. Homogenates were centrifuged at 500 x g for 15 min at 4 °C, followed 
by centrifugation of the supernatant at 200,000 x g for 60 min at 4 °C. Subsequently, the 
pellet was resuspended in buffer A. For all membrane preparations, protein concentration 
was determined using the BioRad protein assay (BioRad Laboratories, Veenendaal, The 
Netherlands).
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Deglycosylation studies and immunoblot analysis. Crude membrane fractions from Sf9 
cells infected with Mrp2-encoding baculovirus and from rabbit kidney were treated with 
PNGase F according to the manufacturer. Protein-equivalents (see figure legends) were 
solubilized in Laemmli's sample buffer supplemented with 100 mM dithiothreitol, heated 
for 10 min at 65 °C, subjected to SDS polyacrylamide gel electrophoresis, and transferred 
to Hybond-C pure nitrocellulose membrane (Amersham, Buckinghamshire, UK) as 
described previously [5]. Transfer of proteins was confirmed by the reversible staining of 
the membrane with Ponceau Red. Subsequently, the blot was blocked for 60 min with 5%  
nonfat dry milk powder in Tris-buffered saline supplemented with 0.3% Tween-20 (TBS-T) 
and washed twice with TBS-T. To detect rabbit Mrp2 proteins, the membrane was 
incubated overnight at 4 0C with antiserum k78mrp2 or k51mrp2 diluted 1:5000 in TBS-T. 
After two times washing for 5 min with TBS-T, the blot was blocked for 30 min as 
described above. The blot was then washed twice with TBS-T and incubated at room 
temperature for 60 min with affinity-purified horseradish peroxidase-conjugated goat anti­
rabbit IgG (Sigma Immunochemicals, St. Louis MO) diluted 1:5000 in TBS-T. Finally, the 
blot was washed twice for 5 min with TBS-T and TBS, respectively. Proteins were 
visualized using enhanced chemiluminescence (Pierce, Rockford IL).
Transport studies in membrane vesicles. Uptake of [3H]LTC4 into membrane vesicles was 
measured by using a rapid filtration technique [19]. Briefly, membrane vesicles (20 ^g 
protein-equivalent) were rapidly thawed and incubated at 37 °C  in the presence of 4 mM 
MgATP, 10 mM MgCh, 10 mM creatine phosphate, 100 ^g/ml creatine kinase, and 3 nM 
[3H]LTC4 in a final volume of 120 ^ l of TS-buffer (10 mM Tris-Hepes, 250 mM sucrose, pH
7.4). At indicated times, 20-yl samples were taken from the reaction mixture, diluted in 
ice-cold TS-buffer and filtered through nitrocellulose filters (0.45 ^m pore size, Schleicher 
& Schuell, Dassel, Germany) using a filtration device (Millipore Corp., Bedford, MA). 
Filters were washed once with 5 ml TS-buffer and dissolved in liquid scintillation fluid to 
determine the bound radioactivity. In control experiments, 4 mM MgATP was replaced by 
4 mM 5'-AMP. Net ATP-dependent transport was calculated by subtracting values in the 
presence of 5'-AMP from those in the presence of ATP. Uptake of [3H]E217GG at a final 
concentration of 50 nM was done similarly as described for [3H]LTC4, except that a 50 ^g 
protein-equivalent of membrane vesicles was used.
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Fig. 1. Immunoblot analysis of Sf9 cells infected with recombinant baculovirus encoding Mrp2.
A, Crude membrane fractions were isolated from Sf9 cells infected with a control baculovirus (Sf9-c) 
or recombinant baculovirus encoding Mrp2 (Sf9-Mrp2). Proteins (5 /jg) were separated on a 6% SDS 
polyacrylamide gel, transferred to a nitrocellulose membrane, and incubated with Mrp2 polyclonal 
antiserum k78mrp2 or k51mrp2. Proteins were visualized using enhanced chemiluminescence. 
Sizes of protein standards are indicated in kilodaltons. B, Protein-equivalents of crude membrane 
fractions from rabbit kidney (20 jg ) and from Sf9 cells infected with recombinant baculovirus 
encoding Mrp2 (5 jg ), were treated without (-) or with (+) PNGase F and subjected to immunoblot 
analysis using antiserum k78mrp2 as described in A.
Results
Sf9 insect cells were infected with recombinant baculovirus encoding rabbit Mrp2 
or control baculovirus. Crude membranes were prepared and subjected to 
immunoblot analysis using antiserum k78mrp2 and k51mrp2. Both antisera 
detected a protein of ~180 kDa in membranes from cells infected with 
baculovirus encoding Mrp2 (Fig. 1A, Sf9-Mrp2) but not in membranes from cells 
infected with control baculovirus (Fig. 1A, Sf9-c). This size is smaller than 
cMoat/Mrp2 detected in liver and kidney, which has been reported to have a 
molecular weight of ~190 kDa [3,27,33]. To investigate whether this difference in
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molecular weight can be attributed to differences in post-translational 
modifications, crude membrane fractions from rabbit kidney and Sf9-Mrp2 cells 
were treated with or without PNGase F and analyzed by immunoblotting using 
antiserum k78mrp2 (Fig. 18). Deglycosylation reduced the molecular weight of 
rabbit kidney Mrp2 from ~190 to 175 kDa, which is the size that can be deduced 
from the rabbit mrp2 cDNA sequence [37,38]. Treatment with PNGase F reduces 
the molecular mass of Mrp2 in Sf9 cells only slightly to 175 kDa. This indicates 
that in Sf9 cells, Mrp2 is less glycosylated than in rabbit kidney.
Fig. 2. Comparison of Mrp2 protein 
levels in Sf9 cells, liver and renal 
proximal tubules. Protein-equivalents 
of crude membrane fractions isolated 
from Sf9-Mrp2 cells (1, 4 ug), rabbit 
liver (5, 20 ug) and rabbit renal 
proximal tubules (5, 20 ug) were 
separated on a 7.5% SDS 
polyacrylamide gel and subjected to 
immunoblot analysis using antiserum 
k78mrp2. Proteins were visualized 
using enhanced chemiluminescence.
To determine the expression level of rabbit Mrp2 in Sf9 cells, we subjected crude 
membrane fractions from Sf9-Mrp2 cells, rabbit liver and rabbit renal proximal
Sf9-Mrp2
1 4
5 20
liver
renal
proximal
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tubular cells to immunoblot analysis using antiserum k78mrp2 (Fig. 2). A 1 jg  
protein-equivalent of crude membranes from Sf9-Mrp2 cells was sufficient to 
detect Mrp2. Approximately 20 jg  protein-equivalent of crude membranes from 
liver and renal proximal tubules was needed to detect a similar amount of Mrp2 
protein as present in 4 jg  protein-equivalent of Sf9-Mrp2 crude membranes.
Fig. 3. Time course of net ATP-dependent uptake of [3H]LTC4 and [3H]E217$G in Sf9-Mrp2 and Sf9- 
c membrane vesicles. Membrane vesicles from Sf9-c (open symbols) and Sf9-Mrp2 (closed symbols) 
were incubated in TS-buffer (10 mM Tris-HCl, 250 mM sucrose pH 7.4) at 37 °C  for the times 
indicated. Uptake was determined for [3H]LTC4 (left) and [3H]E217fiG (right) at final concentrations 
of 3 nM and 50 nM, respectively. Net ATP-dependent transport was calculated by subtracting 
values in the presence of 4 mM 5'-AMP from those in the presence of 4 mM ATP. Data points 
represent the mean ± standard error of three or four determinations in a typical experiment.
To investigate whether recombinant rabbit Mrp2 is functional, we investigated 
uptake of [3H]LTC4 and [3H]E217£G into Sf9-Mrp2 and Sf9-c membrane vesicles. 
Sf9-Mrp2 membrane vesicles exhibit net ATP-dependent uptake of both [3H]LTC4 
(Fig. 3, left) and [3H]E217£G (Fig. 3, right) which was at the 2-min time point ~11- 
fold higher than in Sf9-c membrane vesicles. In the presence of 5'-AMP, transport 
of either substrate was hardly detectable in Sf9-Mrp2 membrane vesicles and was
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similar to that in Sf9-c membrane vesicles in the presence of 5'AMP or ATP (not 
shown). Initial rates of uptake for 3 nM [3H]LTC4 and 50 nM [3H]E217£G were 75 
and 450 fmol/mg/min, respectively.
1/[SUCROSE] (1/M) [ATP] (mM)
Fig. 4. Osmolarity dependence and effect of ATP concentration on [3H]E217fiG uptake in 
Sf9-Mrp2 membrane vesicles. Membrane vesicles from Sf9-Mrp2 cells were incubated with 50 nM 
[3H]E2l7fiG at 37 °C  for 1 min. A, ATP-dependent transport was determined in the presence of 
sucrose concentrations ranging from 250 mM (isotonic condition) to 1000 mM. Initial rates of ATP- 
dependent [3H]E2l7fiG uptake were plotted against the inverse sucrose concentration in the 
reaction mixture. B, ATP-dependent transport was determined at various concentrations of ATP (60­
8000 juM). The graph was plotted by fitting the obtained data according to the Michaelis-Menten 
equation using Prism (GraphPAD, San Diego, CA). Data points in all cases represent the mean ± 
standard error of three determinations in a typical experiment.
To confirm that vesicle-associated increase of ligand reflects transport into a 
vesicular space rather than aspecific binding to the membrane, the medium 
osmolarity dependence of [3H]E217£G uptake was investigated. By increasing the 
extravesicular sucrose concentration from 250 mM (isotonic condition) to 1000 
mM, membrane vesicle space will shrink resulting in decreased uptake. As shown 
in Fig 4A, initial rates of [3H]E217£G uptake in Sf9-Mrp2 membrane vesicles
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decreased linearly with increasing concentrations of sucrose. Transport in 
Sf9-Mrp2 membrane vesicles should also be dependent on the extravesicular 
concentration of ATP. Fig 4B shows that initial rates of [3H]E217SG uptake 
increased with ATP concentrations according to Michaelis-Menten kinetics, 
yielding an apparent Km value of 623 ± 131 uM.
To characterize the inhibitor specificity of rabbit Mrp2, we studied the effect 
of various compounds on [3H]E217SG uptake by Sf9-Mrp2 membrane vesicles 
(Table 1). Phenolphthalein glucuronide exerted a profound inhibition, whereas the 
other two glucuronides (a-naphthyl-S-D-glucuronide, p-nitrophenyl-S-D- 
glucuronide) and FL, a substrate of the classic organic anion transport system [34], 
did not inhibit transport up to 1 mM. Uptake was also susceptible to inhibition by 
LTC4, MTX and FL-MTX. Furthermore, we tested the LTD4-receptor antagonist 
MK571 [13] and the immunosuppressive agent CsA, both of which are inhibitors 
of human MRP1 and rat Mrp2 [3,19] and proved to be inhibitors of rabbit Mrp2.
Discussion
Mrp2 mediates ATP-dependent elimination of conjugated organic anions from 
liver and has recently been cloned from rat [3,11,22,27] and human [28,36]. We 
cloned a rabbit cDNA encoding an ABC-transporter that on basis of similar tissue 
distribution and highest amino acid homology was considered as the rabbit 
homolog of rat Mrp2 [37,38]. On injection of its cRNAs in Xenopus laevis oocytes, 
we observed in a few cases a cAMP-dependent chloride conductance [38]. The 
recent finding that substrates of Mrp2 activate a chloride conductance in 
hepatocytes of normal rats but not in TR" hepatocytes [40], indicates that this 
phenomenon warrants further investigation.
To investigate Mrp2-mediated transport, we here expressed rabbit Mrp2 in Sf9 
cells using recombinant baculovirus. In these cells, Mrp2 is highly expressed, 
although less glycosylated when compared to kidney Mrp2. This is in line with
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TABLE 1
Effect of various compounds on Mrp2-mediated [3H]E217ßG transport
Compound Concentration [3H]E217ßG
uptake
j M % control
None (control) 100
LTC4 10 22 ± 7b
a-Naphthyl-ß-D-glucuronide 1000 94 ± 1
p-Nitrophenyl-ß-D-glucuronide 1000 97 ± 5
Phenolphthalein glucuronide 1000 5 ± 4b
MK571 5 33 ± 3a
Cyclosporin A (CsA) 10 48 ± 1a
Fluorescein (FL) 1000 94 ± 4
Methotrexate (MTX) 1000 55 ± 4a
Fluorescein-methotrexate (FL-MTX) 100 22 ± 7b
Sf9-Mrp2 membrane vesicles were incubated with 50 nM [3H]E2l7fiG at 37 °C  for 1 min 
with or without (control) the compounds as indicated. Net ATP-dependent transport was 
calculated by subtracting values in the presence of 4 mM 5'-AMP from those in the 
presence of 4 mM ATP. Transport was expressed as percent of the control uptake. Data 
represent mean values of three to six determinations (± standard error). a p < 0.05; b p 
< 0.01 (analysis of variance with Bonferroni's correction).
results from other studies in which CFTR and MRP1 were expressed in insect cells 
and detected as an underglycosylated product [8,15]. Results of functional studies 
on MRP1- and CFTR-expressing insect cells are comparable to those obtained from 
transfected eukaryotic cells, indicating that underglycosylation has no significant 
effect on its function [8,15]. This was further corroborated by inhibition of 
glycosylation with tunicamycin in drug-resistant MRP1-expressing human cells [1] 
and, on basis of our studies, can also be concluded for Mrp2.
Based on studies with intact rats and liver canalicular membranes, the 
conjugates E217SG and LTC4 are considered to be substrates for rat Mrp2 [3,35]. In 
addition, ATP-dependent transport of LTC4 has been demonstrated in membrane 
vesicles isolated from NIH/3T3 cells transfected with a rat mrp2 cDNA, and LTC4
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efflux was found in Mrp2-expressing Xenopus oocytes and COS-7 cells [12,22]. In 
the current study, we unambiguously demonstrated that rabbit Mrp2 mediates ATP- 
dependent uptake of both [3H]E217ßG and [3H]LTC4. The initial uptake rates for 
[3H]LTC4 and [3H]E217ßG as well as the Vmax value for ATP using [3H]E217ßG as a 
cosubstrate, are lower than the values described for rat canalicular membrane 
vesicles [3,39] and membrane vesicles from mrp2-transfected NIH/3T3 cells [12]. 
This difference, however, may be explained by the substantially lower substrate 
concentrations that we used. Uptake of [3H]E217ßG in Sf9-Mrp2 membrane vesicles 
was inhibited by LTC4 and phenolphthalein glucuronide. a-Naphthyl-ß-D- 
glucuronide and p-nitrophenyl-ß-D-glucuronide had no significant effect on uptake, 
although both compounds are thought to be Mrp2 substrates. ATP-dependent 
uptake of p-nitrophenyl-ß-D-glucuronide into rat canalicular membrane vesicles has 
been described, whereas in TR" rat livers, a-naphthyl-ß-D-glucuronide excretion was 
impaired [4,17]. These findings suggest that a-naphthyl-ß-D-glucuronide and 
p-nitrophenyl-ß-D-glucuronide are transported with low affinity by Mrp2 and 
consequently, are poor competitive inhibitors themselves. MK571 and CsA are 
inhibitors of human MRP1 and rat Mrp2 [3,19] and, as shown in this study, also 
inhibit rabbit Mrp2-mediated [3H]E217ßG transport. However, it remains to be 
elucidated whether these compounds are Mrp2 substrates.
Mrp2 is expressed not only in liver canalicular membranes [3,27], but also in 
the brush-border membrane of renal proximal tubular cells [33] and small 
intestinal villi (see chapter 3). However, the functional identification of an ATP- 
dependent organic anion transporter in membrane vesicles from renal proximal 
tubular cells, such as in liver canalicular membranes, has never been documented 
[29]. This is mainly due to technical limitations because membrane vesicles of 
renal proximal tubular cells are exclusively orientated right-side out [9]. Recently, 
Masereeuw et al. [24] identified an energy-dependent transport mechanism for 
organic anions in isolated renal proximal tubules from killifish using FL-MTX as a 
substrate. The excretory pathway of FL-MTX was characteristic for its sensitivity to 
LTC4, MTX, CsA and probenecid. In addition, the energy-dependency of this
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pathway was confirmed by treating cells with KCN, which did not influence FL- 
MTX uptake but completely abolished luminal excretion. This suggests that FL- 
MTX may be an Mrp2-substrate for which we provide evidence in this study 
because FL-MTX strongly inhibits [3H]E217SG uptake in Sf9-Mrp2 membrane 
vesicles. In contrast, FL did not inhibit [3H]E217SG uptake, whereas MTX was only 
partially inhibitory. It remains to be established whether Mrp2 directly mediates 
ATP-dependent uptake of FL-MTX.
Besides Mrp2, additional organic anion transporters might be present in 
brush-border membranes of renal proximal tubular cells. For example, excretion of 
FL-MTX was shown to be only partially inhibited by probenecid, whereas the 
probenecid-insensitive mechanism was inhibited completely by verapamil [24]. In 
addition, it has been shown that TR- rats have impaired hepatic excretion of the 
conjugates a-naphthyl-S-D-glucuronide and LTC4, whereas urinary excretion is 
hardly affected [4,10], suggesting that the deficiency of Mrp2 in the kidney can be 
compensated for by other organic anion transporters. Possible candidates might be 
the organic anion transporters Oatpl and Oat-k1, which are both localized in 
brush-border membranes of renal proximal tubular cells [2,25]. Although Oatpl 
and Oat-k1 are structurally not related to Mrp2, these proteins mediate transport of 
Mrp2-substrates, such as E2I 7 SG, LTC4 and MTX [14,20,31]. Furthermore, the 
recently identified family members of human MRP1 (i.e. MRP3, MRP4, and MRP5) 
are all expressed to some extent in the kidney and might also be involved in renal 
organic anion transport [18].
In conclusion, we demonstrated ATP-dependent transport by recombinant 
rabbit Mrp2 and provided new data on inhibitor specificity. In future studies, this 
expression system will be used for identification and characterization of Mrp2- 
substrates, with emphasis on compounds that are excreted by the kidney.
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Summary
Multidrug resistance protein 2 (Mrp2) is an ATP-dependent transporter of anionic 
conjugates. Human MRP2 and rat mrp2 mRNA is abundantly expressed in liver 
and to a lesser extent in small intestine and kidney. In contrast, highest expression 
of rabbit mrp2 mRNA is found in small intestine. In this study, we investigated 
expression and immunolocalization of Mrp2 in rabbit small intestine, liver and 
kidney. Recombinant rabbit Mrp2 expressed in Sf9 cells was detected using 
immunocytochemistry and immunoblotting. Crude membranes of various rabbit 
tissues revealed expression of a 190 kDa protein representing glycosylated Mrp2 
only in small intestine, kidney, and liver. In sections of rabbit small intestine, 
Mrp2-specific immunofluorescence was found at the brush-border (apical) 
membrane of villi decreasing in intensity from the tip to the villus. Like rat Mrp2 
and human MRP2, rabbit Mrp2 is localized to the hepatocyte canalicular (apical) 
membrane and the brush-border membrane of renal proximal tubules. These 
results are in line with the postulated function of Mrp2 in drug excretion into the 
intestinal lumen, urine and bile. In the small intestine, Mrp2 might also function as 
an absorption barrier limiting the oral bioavailability of drugs.
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Introduction
Multidrug resistance protein 2 (MRP2) is an ATP-dependent drug transporter and 
member of the ATP-binding cassette (ABC) superfamily [12]. The substrate 
specificity of rat Mrp2 includes a variety of compounds including unconjugated 
(bromosulphophthalein, folates) and conjugated (leukotriene C4, LTC4; estradiol- 
175-D-glucuronide, E2I 7 SG; bilirubin-glucuronides) organic anions [12,18,40]. 
These substrates have been identified by comparative studies with wildtype rats 
and the hyperbilirubinemic rat strains EHBR and GY/TR" defective for functional 
Mrp2 [2,10,27]. In addition, substrate specificity has been characterized using 
various types of cell lines overexpressing recombinant rat Mrp2 or human MRP2 
[4,6,11,42]. Such transfected cell lines have also indicated that human MRP2 is 
able to confer resistance to various cationic anti-cancer drugs, such as cisplatin, 
vincristine, etoposide and methotrexate [4,9,14].
We have cloned a rabbit ABC-transporter, which shows highest identity to 
MRP2 and functions as an ATP-dependent anionic conjugate transporter upon 
expression in Sf9 cells [42,43]. In agreement with human and rat, expression of 
rabbit mrp2 mRNA is found in kidney, liver, and all parts of the small intestine [2, 
10,15,43]. However, rabbit mrp2 mRNA is most abundantly expressed in small 
intestine, whereas highest expression of human MRP2 and rat mrp2 mRNA is 
found in liver [10,15,43]. Furthermore, immunohistochemistry revealed expression 
of human and rat MRP2/Mrp2 at the apical membrane of renal proximal tubules 
[34,35], whereas expression of rabbit Mrp2 was found at the basolateral 
membrane of renal distal tubules [43]. Therefore, we reanalyzed the expression 
and localization of Mrp2 in rabbit small intestine, kidney and liver by using 
immunoblotting and immunohistochemistry.
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Experimental procedures
Antibodies. Affinity-purified rabbit polyclonal anti-actin antibodies (20-33) were 
purchased from Sigma Immunochemicals (St. Louis MO, USA). 101E12 is a monoclonal 
antibody (mAb) directed against the apical membrane of rabbit renal proximal tubules 
[31]. Polyclonal antibody GP8 was obtained by immunizing guinea pigs with a 
glutathione 5-transferase (GST) fusion protein containing the 159 carboxyl-terminal amino 
acids (1405-1564) of rabbit Mrp2 as described [42].
Membrane isolations. All membrane preparations were performed at 4 °C. Rabbit tissues 
were excised and homogenized in TS-buffer (250 mM sucrose, 10 mM Tris-Hepes, pH
7.4). After centrifugation at 200 x g, the supernatant was centrifuged at 100,000 x g for 30 
min and the pellet of crude membranes was dissolved in TS-buffer. Sf9 cells were infected 
with a recombinant baculovirus encoding Mrp2 or the 5-subunit of the rat H+/K+ ATPase 
(mock) as described [42], washed in phosphate-buffered saline, and resuspended in 
hypotonic buffer (0.5 mM sodium phosphate, 0.1 mM EDTA, pH 7.0) supplemented with 
protease inhibitors (2 mM phenylmethylsulfonyl fluoride, 5 jg/ml aprotinin, 5 jg/ml 
leupeptin, 1 mM pepstatin). Cells were stirred gently on ice for 90 min and the resulting 
lysate was centrifuged at 100,000 x g for 60 min. The pellet of crude membranes was 
resuspended in TS-buffer using a potter homogenizer and the homogenate was 
centrifuged at 12,000 x g for 10 min. The postnuclear supernatant was centrifuged at
100,000 x g for 40 min and the pellet obtained was resuspended in TS-buffer with a tight- 
fitting Dounce (type B) homogenizer. The suspension was layered over 38% sucrose in 5 
mM Hepes/KOH pH 7.4 and centrifuged at 100,000 x g for 2 h. The interphase was 
collected and homogenized with a tight-fitting Dounce (type B) homogenizer and the 
suspension was centrifuged at 100,000 x g for 40 min. The resulting pellet was 
resuspended in TS-buffer and passed through a 27-gauge needle for 30 times. Membrane 
vesicles were frozen and stored at -80 °C until use. Protein concentrations were 
determined using the BioRad protein assay (BioRad Laboratories, Veendendaal, The 
Netherlands). Membranes were treated with PNGase F (New England Biolabs, Leiden, The 
Netherlands) according to the manufacturer.
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Immunoblotting. Protein-equivalents (5 jjg) of membrane preparations were solubilized in 
Laemmli sample buffer, heated at 65 °C  for 10 min, separated on a 6% (for detection of 
Mrp2) or 10% (for detection of fi-actin) polyacrylamide gel, and transferred to Hybond-C 
pure nitrocellulose membrane (Amersham, Buckinghamshire, UK). Transfer of proteins 
was confirmed by the reversible staining of the membrane with Ponceau Red. 
Subsequently, the blot was blocked for 60 min with 5% nonfat dry milk powder in Tris- 
buffered saline supplemented with 0.3% Tween-20 (TBS-T) and washed twice with TBS-T. 
The membrane was incubated at 4 0C for 16 h with polyclonal antibodies GP8 or 20-33 
diluted 1:1000 in TBS-T. After two times washing for 5 min with TBS-T, the blot was 
blocked for 30 min as described above. The blot was then washed twice with TBS-T and 
incubated at room temperature for 60 min with affinity-purified horseradish peroxidase 
(HRP)-conjugated goat anti-guinea pig IgG or affinity-purified HRP-conjugated goat anti­
rabbit IgG (Sigma Immunochemicals, St. Louis MO) diluted 1:5000 in TBS-T. Finally, the 
blot was washed twice for 5 min with TBS-T and TBS, respectively. Proteins were 
visualized using enhanced chemiluminescence (Pierce, Rockford IL).
Immunohistochemistry. Sf9 cells were cultured on coverslips and infected as described 
[42]. Cells were fixed in 100% methanol for 10 min at -20 °C  and air-dryed. Slices of 
rabbit small intestine, liver, and kidney were fixed in 1% (v/v) periodate-lysine- 
paraformaldehyde fixative for 2 h, washed with 20% (w/v) sucrose in phosphate-buffered 
saline, and subsequently frozen in liquid N2 . Coverslips with Sf9 cells and tissue sections 
(7 ywM) were blocked with 10% (v/v) goat serum in TBS for 15 min, washed three times 
with TBS, and incubated with GP8 (diluted 1:50 in TBS) for 16 hours at 4 °C. Kidney 
sections were also incubated with mAb 101E12 (hybridoma culture medium). After 
washing in TBS, coverslips and tissue sections sections were incubated with 1:50 diluted 
tetramethyl rhodamine isothiocyanate (TRITC)-conjugated affinity-purified goat anti-mouse 
Fab (Biomakor, Rehovot, Israel) and/or fluorescein isothiocyanate (FITC)-conjugated 
affinity-purified goat anti-guinea pig IgG (Sigma Immunochemicals, St. Louis MO, USA), 
dehydrated by 100% methanol, mounted in mowiol (Hoechst), and analyzed by 
immunofluorescence microscopy.
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Fig. 1. Sf9 cells overexpressing rabbit Mrp2. Sf9 cells were infected with a recombinant 
baculovirus encoding Mrp2 or the S-subunit of the rat H+/K+ ATPase (mock). A, membrane vesicles 
from infected Sf9 cells were subjected to immunoblot analysis using polyclonal antibody GP8. 
Arrow heads indicate molecular weight in kilodalton (kDa). B, Sf9 cells were cultured on coverslips 
and infected with Mrp2 or H+/K+ ATPase S-subunit (mock) encoding baculovirus. Cells were fixed 
and incubated with GP8 and analyzed by immunofluorescence microscopy. White marker bar at 
the bottom right equilizes in length to 38 /jm.
Results
To investigate the immunolocalization of rabbit Mrp2 in small intestine, kidney, 
and liver, we initially used the rabbit polyclonal antibodies k51mrp2 and 
k78mrp2, which recognize recombinant rabbit Mrp2 expressed in Sf9 cells as 
reported previously [42]. However, these antibodies gave rise to high background 
staining on sections of rabbit tissues. Therefore, a new polyclonal antibody (GP8) 
was raised in guinea pigs directed against the carboxy-terminus of rabbit Mrp2. In 
immunoblot analysis, GP8 detected a single band with a molecular weight of 
~180 kDa in membrane vesicles from Sf9 cells overexpressing Mrp2 (Fig. 1A). As 
assessed by treating membranes with PNGase F, the 180 kDa band represents 
underglycosylated Mrp2 [42]. Furthermore, immunocytochemistry revealed clear
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fluorescence in Sf9 cells overexpressing Mrp2 but not in mock-infected Sf9 cells 
(Fig. 1B).
Rabbit mrp2 mRNA is expressed in small intestine, kidney and liver [43]. To 
investigate the tissue distribution of rabbit Mrp2, crude membranes of various 
rabbit tissues were subjected to immunoblot analysis using GP8. Of all the tissues 
examined, a protein of approximately 190 kDa was detected in crude membranes 
from only liver, kidney and small intestine (Fig. 2A). As an internal control, 
polyclonal antibodies against 5-actin (20-33) detected a protein of about 43 kDa in 
crude membranes of all tissues examined. PNGase F treatment of crude 
membranes from liver, kidney, and small intestine, indicated that the 
immunoreactive band of ~190 kDa represents glycosylated rabbit Mrp2 (Fig. 2B).
The immunolocalization of rabbit Mrp2 was investigated by indirect 
immunofluorescence using polyclonal antibody GP8. PLP-fixed sections of rabbit 
duodenum showed intense immunopositive fluorescence at the brush-border 
membrane of villi (Fig. 3A and B ). The intensity of fluorescence decreased along 
the length of the villus towards the crypts, at which no staining was observed (Fig 
3B and D). Other parts of the small intestine, i.e. submucosa and muscle layers 
were negative (Fig. 3B and C). Sections incubated with preimmune serum or with 
GP8 preincubated with the fusion protein antigen revealed no staining (not 
shown). To confirm that rabbit Mrp2 is the ortholog of human MRP2 and rat Mrp2, 
we investigated the localization of Mrp2 in rabbit kidney and liver. In PLP-fixed 
sections of rabbit kidney, Mrp2 expression was confined to the apical membrane 
of tubules located in the cortex and outer medulla (Fig. 4A). Other parts of the 
nephron, i.e. glomeruli, cells of Henle's ascending and descending loop, distal 
cells, and cells of the cortical and medullary collecting duct, were negative.
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Fig 2. Tissue distribution of rabbit Mrp2. A, crude membranes were prepared from 
rabbit erythrocytes (E), colon (C), heart (H), liver (Li), lung (Lu), kidney (K), and small 
intestine (S) and subjected to immunoblot analysis using polyclonal antibodies GP8 
and 20-33 for detection of rabbit Mrp2 (upper panel) and ß-actin (lower panel), 
respectively. B, crude membranes of kidney, liver, and small intestine were treated 
with PNGase F and subjected to immunoblot analysis using polyclonal antibody GP8.
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Fig. 3. Immunolocalization of Mrp2 in rabbit small intestine. PLP-fixed sections of rabbit small 
intestine were incubated with polyclonal antibody GP8. A and B, Mrp2-specific 
immunofluorescence was located to the apical membrane of the whole villus. D, high 
magnification of a crypt area showing decreasing Mrp2-specific immunofluorescence from the 
lower part of the villus (arrow heads) towards the crypt (arrows). C and E, Phase-contrast 
microscopy of the section identical to B and D, respectively. White marker bar at the bottom left 
equalizes in length to 216 jjm in A and B, and 54 jjM  in D.
76
Immunolocalization of Rabbit Mrp2
Fig. 4. Immunolocalization of Mrp2 in rabbit kidney. PLP-fixed sections of rabbit kidney were 
incubated with polyclonal antibody GP8 preincubated without (A) or with the fusion protein 
antigen (B). A, low magnification showed Mrp2-specific fluorescence in the apical membrane of 
S1-S3 proximal tubules. C and D, high magnification of sections double-labeled with GP8 and 
mAb 101E12. Immunofluorescence specific for Mrp2 and the brush-border membrane are shown 
in C and D, respectively. White marker bar at the bottom left equalizes in length to 56 /jm.
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Fig. 5. Immunolocalization of Mrp2 in rabbit liver. PLP-fixed sections of rabbit liver were labeled 
with polyclonal antibody GP8 preincubated without (A) or with the fusion protein antigen (B) and 
analyzed by immunofluorescence microscopy. Clear Mrp2-specific fluorescence was observed in 
the hepatocyte canalicular membrane (A ). White marker bar at the bottom right equalizes in length 
to 56 jum.
Sections incubated with GP8 preincubated with the fusion protein antigen (Fig. 
4B) or preimmune serum (not shown) revealed no staining. To confirm the 
localization of Mrp2, sections were simultaneously incubated with mAb 101E12, 
which recognizes an epitope in the proximal tubule brush-border membrane of 
segments S1-S3. Immunofluorescence specific for Mrp2 (Fig. 4C) colocalized with 
fluorescence specific for the brush-border membrane (Fig. 4D). This colocalization 
was further corroborated by superimposition of both fluorescences (not shown). In 
sections of rabbit liver, immunofluorescence specific for Mrp2 revealed a staining 
characteristic for the canalicular membrane (Fig. 5A). A similar staining has been 
shown in rat and human liver using a monoclonal antibody directed against rat 
Mrp2 [27,28]. Polyclonal antibody GP8 pre-incubated with the fusion protein 
antigen (Fig. 5B) or preimmune serum (not shown) revealed no staining.
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Discussion
We investigated the immunolocalization of rabbit Mrp2. In agreement with the 
tissue distribution of rabbit mrp2 mRNA, immunoblot analysis showed expression 
of Mrp2 exclusively in liver, kidney, and small intestine crude membranes. Rabbit 
Mrp2 was localized to the brush-border membrane of small intestinal villi, and 
similar to human MRP2 and rat Mrp2, to the hepatocyte canalicular membrane 
and the brush-border membrane of renal proximal tubules.
Immunoblot analysis of Mrp2 expression in rabbit tissues as shown here is in 
agreement with that reported for Mrp2 in rat tissues [35]. However, the expression 
level of rabbit Mrp2 is much higher in kidney than liver, whereas the opposite has 
been shown for rat Mrp2 [35]. A possible explanation for this difference might be 
that total crude membranes were used for detection of Mrp2 in rabbit liver, 
whereas rat Mrp2 was determined in purified canalicular (apical) membrane 
vesicles [35]. Since the liver canalicular membrane accounts for only 13% of the 
total plasma membrane, the amount of Mrp2 detected in rabbit liver might be 
underestimated. Another explanation might be that our antibody cross reacts with 
other members of the MRP-family. Indeed, human MRP3, MRP4, MRP5, and 
MRP6 mRNA is expressed in kidney to some extent [13,15,16]. However, MRP3-5 
are among other tissues also expressed in lung and colon, but on immunoblot no 
protein was detected in crude membranes of these tissues using polyclonal 
antibody GP8. In addition, no proteins were detected in erythrocytes, in which 
MRP1 and at least another ATP-dependent anionic conjugate transporter is 
expressed [30,33,44]. Furthermore and of most importance, murine Mrp1 [29], 
human MRP3 [17], human MRP5 [3], and rat Mrp6 [20] are expressed in basal­
lateral membranes of epithelial cells.
Comparitive studies with wildtype and Mrp2-deficient (GY/TR-, EHBR) rats 
using isolated canalicular membrane vesicles or perfused livers, have indicated 
that Mrp2 is important in the biliary excretion of multiple conjugated and 
unconjugated organic anions [37]. Excretion across the canalicular membrane of
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for example, a-naphthyl-S-D-glucuronide [5], E3040-glucuronide [38,39], 
cefpiramide [24], and HSR-903 [25] is markedly decreased in livers from EHBR 
and GY/TR- rats. On the other hand, uptake studies with canalicular membrane 
vesicles using E3040-glucuronide or pravastatin as a substrate provided clear 
evidence for an additional ATP-dependent transport system alongside MRP2 
[26,45]. Furthermore, biliary excretion of paracetamol glucuronide, which is 
sensititive to probenecid [32], is not mediated by Mrp2 [41]. The mechanism 
governing the renal and intestinal excretion of conjugated organic anions by MRP2 
is still not elucidated. An ATP-dependent efflux mechanism for the organic anions 
fluorescein-methotrexate (FL-MTX) and lucifer yellow (LY) has been characterized 
in killifish renal proximal tubules [21,22]. An Mrp2 ortholog is probably involved, 
since efflux was partly inhibited by LTC4 and immunohistochemistry using a 
polyclonal antibody directed against rabbit Mrp2 revealed staining of the killifish 
proximal tubule brush-border membrane [21-23]. The few data available indicate 
that, in contrast to their impaired biliary excretion, the renal excretion of 
a-naphthyl-S-D-glucuronide [5], E3040-glucuronide [39], cefpiramide [24], and 
HSR-903 [25] is unaltered in EHBR and GY/TR" rats. This indicates that other 
transport mechanisms exist for the renal excretion of organic anions, which 
compensate for the absence of Mrp2. Like urinary excretion, intestinal excretion of 
a-naphthyl-S-D-glucuronide in GY/TR- rats is not impaired also suggesting 
additional transport pathways [5].
Besides Mrp2, the brush-border membrane of renal proximal tubules and 
small intestine also contains the MDR1-gene encoded drug-efflux pump 
P-glycoprotein (Pgp) [1,7]. Humans express one gene product, whereas mice have 
two, i.e. encoded by the mdr1a and mdr1b genes [7]. Pgp transports a variety of 
compounds in an ATP-dependent fashion, including chemotherapeutic agents, 
hormones and HIV-1 protease inhibitors [8,19]. Mice with a disruption of the 
mdr1a gene [mdrla (-/-)], which is normally expressed in small intestine, show a 
2-4 fold increase in plasma concentration of indinavir, nelfinavir or saquinavir 
compared to wildtype mice [19]. Since Mrp2 has been proposed to mediate
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transport of at least the latter compound [8], Mrp2 might also be a determinant in 
the low oral bioavailability of certain (antiviral) drugs.
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Summary
The present study examined how the multidrug resistance protein 2 (MRP2), which 
is an ATP-dependent anionic conjugate transporter, also mediates transport of the 
chemotherapeutic cationic drug vinblastine (VBL). W e show that ATP-dependent 
[3H]VBL (0.2 jM ) uptake into membrane vesicles from Sf9 cells infected with a 
baculovirus encoding rabbit Mrp2 (Sf9-Mrp2) was similar to vesicles from mock- 
infected Sf9 cells (Sf9-mock), but could be stimulated by reduced glutathione 
(GSH) with a half maximum stimulation of 1.9 ± 0.1 mM. At 5 mM GSH, initial 
ATP-dependent [3H]VBL uptake rates were saturable with an apparent Km of 1.5 ± 
0.3 jM . The inhibitory effect of VBL on Mrp2-mediated ATP-dependent transport 
of the anionic conjugate [3H]leukotriene C4 ([3H]LTC4) was potentiated by 
increasing GSH concentrations. Membrane vesicles from Sf9-Mrp2 cells exhibited 
a — 7-fold increase in initial GSH uptake rates compared to membrane vesicles 
from Sf9-mock cells. Uptake of [3H]GSH was osmotically sensitive, independent of 
ATP, and trans-inhibited by GSH. The anionic conjugates estradiol-17S-D- 
glucuronide and LTC4 cis-inhibited [3H]GSH uptake but only in the presence of 
ATP. Whereas ATP-dependent [3H]VBL uptake was stimulated by GSH, VBL did 
not affect [3H]GSH uptake. In conclusion, our results show that GSH is required for 
Mrp2-mediated ATP-dependent VBL transport and that Mrp2 transports GSH 
independent of VBL.
(available online at http://molpharm.aspetjournals.org)
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Introduction
The multidrug resistance protein 2 (MRP2; or canalicular multispecific organic 
anion transporter, cMOAT) is an ATP-dependent anionic conjugate transporter, 
which is expressed in small intestine and apical (canalicular) membranes of 
hepatocytes and renal proximal tubules (for review see ref. 13). Substrates of 
MRP2 include glutathione S-conjugates, such as S-(dinitrophenyl)-glutathione 
(DNP-SG), S-(prostaglandin Ai)-glutathione and leukotriene C4 (LTC4) and 
glucuronide conjugates of bilirubin and estradiol [7,10,11,21,32]. MRP2 belongs 
to a branch of at least six multidrug resistance proteins (MRP1-MRP6) within the 
superfamily of ATP-binding cassette (ABC) proteins (see for latest update: 
http://www.med.rug.nl/mdl/tab3.htm). Involvement in the phenotype of multidrug 
resistance, however, has only been proven for MRP1 because it is frequently 
overexpressed in various drug-selected cancer cell lines and transfection of drug- 
sensitive cells with an MRP1 cDNA results in resistance to various drugs (for 
review see ref. 6). Recently, overexpression of MRP2 mRNA and MRP2 protein 
levels has been found in a few cancer cell lines selected for cis- 
diamminedichloroplatin (CDDP) [15]. Downregulation of endogenous MRP2 
protein levels in HepG2 cells via antisense transfection reduces resistance to 
various chemotherapeutic drugs, including vincristine (VCR) and CDDP [14]. 
MDCKII cells stably transfected with an MRP2 cDNA show enhanced vinblastine 
(VBL) transport across the apical membrane [7].
The mechanism by which MRP2 mediates transport of cationic 
chemotherapeutic drugs is unknown. Since MRP1 requires reduced glutathione 
(GSH) for ATP-dependent VCR uptake into membrane vesicles [19], MRP2- 
mediated drug transport might also be dependent on GSH. Furthermore, it has 
been suggested that GSH itself is an MRP2 substrate, but reports are contradictory 
[8,24]. The rat strains EHBR and TR", which lack functional Mrp2, are 
characterized by hyperbilirubinemia as well as low biliary GSH contents 
compared to wildtype rats [13,24,30]. However, GSH uptake into EHBR liver
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canalicular membrane vesicles has been reported to be similar to wildtype liver 
canalicular membrane vesicles [8]. Furthermore, both wildtype and EHBR 
canalicular membrane vesicles only harbor ATP-independent GSH transport 
systems, suggesting that Mrp2 is not involved in GSH transport [2,8].
The purpose of this study was to investigate the mechanism by which MRP2 
mediates ATP-dependent transport of the cationic drug VBL. By using membrane 
vesicles from Sf9 cells overexpressing rabbit Mrp2 as described previously [32], 
we determined uptake of [3H]VBL with emphasis on a putative role for GSH. In 
addition, we investigated whether GSH itself is an Mrp2 substrate and how VBL 
and GSH affect Mrp2-mediated ATP-dependent uptake of [3H]LTC4.
Experimental procedures
Materials. [G-3H]VBL sulphate (15.5 Ci/mmol) was purchased from Amersham 
International (Buckinghamshire, UK). [14, 15, 19, 20-3H]LTC4 (165 Ci/mmol) and 
[glycine-2-3H]GSH (44.8 Ci/mmol) were purchased from NEN Life Science Products 
(Hoofddorp, The Netherlands). E217GG, LTC4 , glucuronate, BSA, S-methyl-GSH, GSH, 
ATP, DTT and VBL were purchased from Sigma (Zwijndrecht, The Netherlands). Acivicin 
was purchased from ICN Biochemicals (Cleveland, Ohio, USA). Creatine phosphate and 
creatine kinase were purchased from Boehringer Mannheim (Almere, The Netherlands). 
Glassfiber GF/F filters were purchased from Whatmann (Omnilabo International, Breda, 
The Netherlands). ME-25 membrane filters were purchased from Schleicher and Schuell 
(Dassel, Germany). MK571 was a generous gift of Dr. A.W. Ford-Hutchinson (Merck 
Frosst, Center for Therapeutic Research, Quebec, Canada).
Expression of Mrp2 in Sf9 cells and isolation of membrane vesicles. Sf9 cells (106/ml) were 
grown as 100 ml suspension cultures and infected for three days at a multiplicity of 
infection of 1-5 with a recombinant baculovirus encoding rabbit Mrp2 (Sf9-Mrp2) as 
described recently [32]. For control experiments, Sf9 cells were infected with a 
baculovirus encoding the G-subunit of rat H+/K+ ATPase (Sf9-mock). Membrane vesicles 
were isolated as described [32]. Briefly, cells were collected, resuspended in hypotonic
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buffer (0.5 mM sodium phosphate, 0.1 mM EDTA, pH 7.0) and centrifuged at 100,000 x g 
for 30 min. The pellet of crude membranes was resuspended in TS-buffer (10 mM Tris- 
Hepes, 250 mM sucrose pH 7.4) and centrifuged at 12,000 x g for 10 min. The 
postnuclear supernatant was centrifuged at 100,000 x g for 40 min and the pellet obtained 
was resuspended in TS-buffer, layered over 38% sucrose in 5 mM Hepes/KOH pH 7.4 
and centrifuged at 100,000 x g for 120 min. The interphase was collected, homogenized 
and centrifuged at 100,000 x g for 40 min. The resulting pellet was resuspended in TS- 
buffer and passed through a 27-gauge needle for 30 times. Membrane vesicles were 
frozen and stored at -80 °C  until use.
Transport studies. Uptake of [3H]VBL into membrane vesicles was performed as described 
recently [9,32], with modifications. Briefly, membrane vesicles (20 jg  protein-equivalent) 
were thawed for 1 min at 37 °C  and added to pre-warmed TS-buffer supplemented with 
an ATP-regeneration mix (4 mM ATP, 20 mM MgCb, 10 mM creatine phosphate, 100 
jg/ml creatine kinase) and 0.2 jM  [3H]VBL in a final volume of 60 j l .  The reaction 
mixture was incubated at 37 °C  and at indicated times samples were taken from the 
mixture, diluted in 1 ml ice-cold TS-buffer and filtered through Whatman GF/F filters 
(soaked overnight in 5% (w/v) bovine serum albumin at 37 °C) using a filtration device 
(Millipore Corp., Bedford, MA). Filters were washed once with ice-cold 5 ml TS-buffer and 
dissolved in liquid scintillation fluid to determine the bound radioactivity. Uptake of 
[3H]LTC4 at 2 nM was performed as described [32]. Uptake of [3H]GSH at 37 °C  was 
performed according to the same procedure as for [3H]LTC4, except that 5 mM DTT was 
added at every GSH concentration used and that samples were filtered through ME-25 
membrane filters. Uptake of GSH was not affected by 250 jM  acivicin, indicating 
negligible activity of y-glutamyltransferase in membrane vesicles of Sf9 cells. In all uptake 
experiments, net ATP-dependent transport was calculated by subtracting values in the 
absence of ATP from those in the presence of ATP. Measurements were corrected for the 
amount of ligand bound to the filters (usually < 2% of total radioactivity).
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TABLE 1
ATP-dependent uptake of [3H]VBL into membrane vesicles of Sf9-Mrp2 and 
Sf9-mock cells
Compound ATP-dependent [3H]VBL uptake
Sf9-Mrp2 Sf9-mock
pmol/mg/2 min pmol/mg/2 min
Control 5.0 ± 1.0 5.1 ± 1.2
GSH 23.1 ± 0^0. 4.9 ± 0.5
GSH + MK571 12.0 ± 1 1 a,b n.d.
5-methyl-GSH 15.2 ± 0. 4.6 ± 0.7
DTT 4.8 ± 1.2 5.3 ± 0.9
Glucuronate 4.9 ± 0.8 5.0 ± 1.2
Membrane vesicles were incubated in TS-buffer with 0.2 j M  [3H]VBL and an ATP- 
regenerating system at 37 °C for 2 min in the absence or presence of the compounds as listed 
below. All compounds were used at a concentration of 5 mM, except for MK571 (0.1 mM). 
ATP-dependent [3H]VBL uptake was calculated by subtracting values in the absence of ATP 
from those in the presence of 4 mM ATP. Data are mean ± S.E. from two experiments 
performed in triplicate. ap < 0.01 compared to control; bp < 0.01 compared to uptake in 
the presence of GSH but absence of MK571 (analysis of variance with Bonferroni's 
correction); n.d., not determined.
Results
We investigated uptake of [3H]VBL into membrane vesicles prepared from Sf9 cells 
infected with a baculovirus containing a rabbit mrp2 cDNA (Sf9-Mrp2). We have 
recently shown that these membrane vesicles contain functional Mrp2 as assessed 
by uptake studies with [3H]LTC4 and estradiol-17£-D-[3H]glucuronide [32]. As 
shown in Table 1, ATP-dependent uptake of 0.2 j M  [3H]VBL into Sf9-Mrp2 
membrane vesicles was 5 pmol/mg/2 min and did not differ from uptake into 
membrane vesicles from Sf9 cells infected with a baculovirus encoding the £- 
subunit of rat H+/K+ ATPase (Sf9-mock). In the presence of 5 mM GSH, however, 
ATP-dependent uptake of [3H]VBL into Sf9-Mrp2 membrane vesicles increased
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TIME (min) TIME (min)
Fig. 1. Time course of GSH-stimulated ATP-dependent [3H]VBL transport by Mrp2. Membrane 
vesicles prepared from Sf9-Mrp2 and Sf9-mock cells were incubated in TS-buffer with 0.2 j M  
[3H]VBL and 5 mM GSH at 37 °C. Samples were taken from the reaction mixture for the times 
indicated. A, GSH-stimulated [3H]VBL uptake into membrane vesicles from Sf9-Mrp2 in the absence 
(open circles) or presence (closed circles) of ATP. B, net GSH/ATP-dependent [3H]VBL uptake into 
membrane vesicles of Sf9-mock (open squares) and Sf9-Mrp2 (closed squares) cells. Data are mean 
± S.E. from two experiments performed in triplicate.
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Fig. 2. Osmolarity dependency of GSH- 
stimulated ATP-dependent [3H]VBL 
transport by Mrp2. GSH/ATP-dependent 
[3H]VBL uptake into Sf9-Mrp2 membrane 
vesicles was determined for 2 min in the 
presence of sucrose concentrations ranging 
from 250 mM (isotonic condition) to 1000 
mM. Net GSH/ATP-dependent [3H]VBL 
transport was plotted against the inverse 
sucrose concentration in the reaction 
mixture. Linear fitting of the obtained data 
was performed using GraphPad Prism 
version 3.00 for Windows (GraphPad 
Software, San Diego CA, USA). Data are 
mean ± S.D. from one experiment 
performed in triplicate.
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5-fold. The leukotriene D4-receptor antagonist MK571 [12], which is an inhibitor of 
Mrp2-mediated transport [5,32], inhibited GSH-stimulated ATP-dependent [3H]VBL 
uptake by ~ 60 %. S-methyl-GSH also increased ATP-dependent [3H]VBL uptake, 
however, this stimulation was 55% as compared with GSH. Glucuronate and 
dithiothreitol (DTT), which was used to maintain GSH in the reduced form [2], did 
not stimulate uptake.
In the presence of GSH and ATP, Sf9-Mrp2 membrane vesicles exhibited time- 
dependent uptake of [3H]VBL (Fig. 1A). In the absence of ATP, GSH-stimulated 
[3H]VBL uptake into Sf9-Mrp2 membrane vesicles was low. For Sf9-Mrp2 
membrane vesicles, initial uptake rates of net GSH-stimulated ATP-dependent 
[3H]VBL were 5.2 + 0.7 pmol/mg/20 sec (Fig. 1ß). In contrast, transport into Sf9- 
mock membrane vesicles was independent of time (4.9 + 0.5 pmol/mg) and 
probably reflects unspecific membrane binding. To confirm that vesicle-associated 
increase of ligand reflects transport into a vesicular space, the effect of medium 
osmolarity on [3H]VBL uptake was investigated (Fig. 2). GSH-stimulated ATP- 
dependent [3H]VBL uptake into Sf9-Mrp2 membrane vesicles decreased linearly 
with increasing concentrations of sucrose. Since vesicle space decreases with 
increasing osmolarity, extrapolation of the data to zero vesicle space indicates that 
5.0 + 0.6 pmol VBL/mg protein is bound to the vesicle membrane.
To further investigate GSH-stimulated VBL transport by Mrp2, initial transport 
rates were determined at various concentrations of [3H]VBL (Fig. 3A). In the 
presence of 5 mM GSH, initial ATP-dependent [3H]VBL uptake rates increased 
with increasing VBL concentrations. Fitting of the obtained data according to the 
Michaelis-Menten equation revealed a Km of 1.5 + 0.3 jM  and Vmax of 89 + 6 
pmol/mg/20 sec. We also investigated the GSH concentration dependency of 
Mrp2-mediated ATP-dependent VBL transport (Fig 3ß). Initial ATP-dependent 
[3H]VBL uptake rates increased with increasing GSH concentrations to a maximum 
at 10 mM. According to Michaelis-Menten kinetics, half-maximum stimulation was 
determined at a GSH concentration of 1.9 + 0.1 mM.
93
Chapter Four
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Fig. 3. VBL and GSH concentration dependency of GSH-stimulated ATP-dependent [3H]VBL 
transport by Mrp2. A, membrane vesicles prepared from Sf9-Mrp2 cells were incubated at 37 °C  
for 20 sec in TS-buffer supplemented with 5 mM GSH and [3H]VBL concentrations ranging from 0.2
- 5 /jM. B, Sf9-Mrp2 membrane vesicles were incubated at 37 °C  for 20 sec in TS-buffer 
supplemented with 0.2 j M  [3H]VBL and GSH concentrations ranging from 0.5 - 40 mM. All data 
were corrected for binding of VBL to the vesicle membrane and were fitted according to the 
Michaelis-Menten equation using GraphPad Prism version 3.00 for Windows (GraphPad Software, 
San Diego CA, USA). Data are mean from two experiments performed in triplicate (± S.E.).
We investigated the effect of GSH and VBL on ATP-dependent uptake of the high- 
affinity substrate LTC4 into Sf9-Mrp2 membrane vesicles. As shown in Fig. 4, initial 
rates of ATP-dependent [3H]LTC4 uptake were not inhibited but rather stimulated 
by GSH at concentrations of 0.1, 1 and 5 mM. VBL (0.1 mM) was only a poor 
inhibitor of initial [3H]LTC4 uptake rates. However, the inhibitory effect of VBL 
(20%) was greatly stimulated in the presence of 0.1, 1 and 5 mM GSH to 72, 82 
and 95%, respectively.
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Fig 4. Effect of GSH and VBL on Mrp2- 
mediated [3H]LTC4 transport. Sf9-Mrp2 
membrane vesicles were incubated 
with 2 nM [3H]LTC4 at 23 °C  for 30 sec 
in the absence (control) or presence of 
VBL (0.1 mM) and/or GSH at 
concentrations as indicated. Transport 
was expressed as percent inhibition of 
net ATP-dependent [3H]LTC4 uptake in 
the absence of GSH and VBL. Final 
concentrations of the dissolvent 
dimethylsulfoxide were < 0.1%. Data 
are mean ± S.E. from two experiments 
performed in triplicate.
To investigate whether GSH itself is an Mrp2 substrate, we measured uptake of 
[3H]GSH at concentrations of 0.1 and 5 mM. Sf9-Mrp2 membrane vesicles 
exhibited time-dependent uptake of [3H]GSH at 0.1 mM, however, uptake was 
only modestly increased as compared to uptake into Sf9-mock membrane vesicles 
(Fig. 5A). At 5 mM, [3H]GSH was taken up into Sf9-Mrp2 membrane vesicles with 
an initial rate of 1.4 ± 0.3 nmol/mg/min, which was ~ 7-fold higher compared to 
initial rates in Sf9-mock membrane vesicles (Fig. 58). In the presence of ATP, time- 
dependent uptake of [3H]GSH (0.1 or 5 mM) into Sf9-Mrp2 and Sf9-mock 
membrane vesicles was not significantly different from uptake in the absence of 
ATP (Fig. 5^ and 8). Uptake of [3H]GSH was sensitive to osmolarity, indicating 
that vesicle-associated [3H]GSH levels represent true uptake into membrane 
vesicles rather than binding to the vesicle membrane (Fig. 5C).
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Fig. 5. Time course and osmolarity 
dependency of Mrp2-mediated [3H]GSH 
transport. A and B, membrane vesicles 
prepared from Sf9-Mrp2 (squares) and Sf9- 
mock (circles) cells were incubated at 37 °C in 
TS-buffer with [3H]GSH at concentrations of 
0.1 mM (A) or 5 mM (B) in the presence 
(closed symbols) or absence (open symbols) of 
ATP. Data are mean ± S.E. from two 
experiments performed in triplicate.
C, [3H]GSH uptake into Sf9-Mrp2 membrane 
vesicles was determined for 4 min in the 
presence of sucrose concentrations ranging 
from 250 mM (isotonic condition) to 1000 
mM. [3H]GSH transport was plotted against the 
inverse sucrose concentration in the reaction 
mixture. Linear fitting of the obtained data was 
performed using GraphPad Prism version 3.00 
for Windows (GraphPad Software, San Diego 
CA, USA). Data are mean ± S.D. from one 
experiment performed in triplicate.
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Preloading of Sf9-Mrp2 membrane vesicles with 5 mM GSH reduced initial 
[3H]GSH uptake rates by ~85% either in the presence or absence of ATP (Table 
2). Initial [3H]GSH uptake rates were also inhibited by LTC4, estradiol-17S-D- 
glucuronate (E2I 7SG) and MK571 but only in the presence of ATP, whereas 
S-methyl-GSH had no effect (Table 2).
TABLE 2
Effect of various compounds on [3H]GSH uptake into membrane 
vesicles of Sf9-Mrp2 cells
Compound [3H]GSH uptake
+ ATP -ATP
Control 100 100
GSH (5 mM, trans) 12 ± 3a 15 ± 4a
S-methyl-GSH (5 mM) 98 ± 5 1 0 0 + 2
LTC4 (5 ^M) 23 ± 5a 9 7 + 1 7
E2 I 7 SG (0.1 mM) 50 + 12a 8 9 + 1 2
MK571 (0.1 mM) 32 + 7a 9 9 + 7
VBL (0.2 j jM) 9 8 + 5  9 8 + 1 0
VBL (0.1 mM) 1 0 2 + 3  1 0 7 + 3
Membrane vesicles were incubated in TS-buffer with 5 mM [3H]GSH at 37 °C for 
1 min in the absence or presence of ATP supplemented with or without (control) 
the compounds as listed below. The trans effect of GSH was studied by 
preloading Sf9-Mrp2 membrane vesicles with 5 mM GSH for 1 hour at 37 °C and 
resuspending them in TS-buffer with [3H]GSH. Transport was expressed as 
percent of the control. Data are mean ± S.E. from two experiments performed in 
triplicate. ap < 0.01 (analysis of variance with Bonferroni's correction). Control 
uptake of [3H]GSH into Sf9-Mrp2 membrane vesicles was 1.3 ± 0.2 nmol/mg/min 
in the presence or absence of ATP.
Recently, Loe et al. have demonstrated that VCR stimulates GSH uptake into 
membrane vesicles from MRP7-transfected HeLa cells, providing evidence for a 
VCR/GSH cotransport mechanism [20]. In view of a possible VBL/GSH cotransport 
mechanism by Mrp2, we investigated the effect of various VBL concentrations on 
uptake of [3H]GSH into Sf9-Mrp2 membrane vesicles. However, the initial uptake 
rate of [3H]GSH at 0.1 mM (95 ± 12 pmol/mg/min; n = 2) or 5 mM (1.3 ± 0.2
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nmol/mg/min; n = 2) was not affected by either 0.2 jM , 10 jM  or 0.1 mM VBL 
(Table 2 and not shown). Furthermore, none of these VBL concentrations affected 
uptake of [3H]GSH at 5 mM for 4 min (not shown).
Discussion
The present study demonstrates that the ATP-dependent anionic conjugate 
transporter Mrp2 requires GSH for ATP-dependent transport of the cationic drug 
VBL. S-Methyl-GSH also stimulated ATP-dependent VBL transport but to a lesser 
extent than GSH, whereas, glucuronate was not able to induce VBL transport. 
These results are in line with previous reports showing that MRP1-mediated VCR 
transport is stimulated by GSH and to a lesser extent by S-methyl-GSH but not by 
glucuronate [19,20]. Furthermore, we show that stimulation of Mrp2-mediated 
ATP-dependent VBL transport by GSH is saturable with a half maximum 
stimulation at 1.9 mM. In presence of 5 mM GSH, saturability of transport is 
observed at increased VBL concentrations with a Km of 1.5 jM . Moreover, the 
small inhibitory effect of VBL on Mrp2-mediated ATP-dependent [3H]LTC4 
transport was potentiated by increasing the GSH concentration.
Secondly, we show that membrane vesicles from Sf9-Mrp2 cells exhibited a 
— 7-fold increase in initial GSH uptake rates compared to membrane vesicles from 
Sf9-mock cells. Uptake of GSH was sensitive to medium osmolarity, independent 
of ATP and almost completely abolished when membrane vesicles were preloaded 
with GSH. Initial GSH uptake rates in Sf9-Mrp2 membrane vesicles were inhibited 
by the anionic conjugates LTC4 and E217SG but only in the presence of ATP. 
These results suggest that Mrp2 is permeable for GSH and that the site for GSH 
permeability interacts with the site for active transport of anionic conjugates. In 
this respect, MK571 inhibits both Mrp2-mediated ATP-dependent anionic 
conjugate transport and ATP-independent GSH transport (ref. 32 and this study). 
Similarly to our results, GSH permeability has recently been shown for the ATP- 
dependent chloride channel CFTR, which belongs to the MRP branch of ABC-
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transporters [18]. Alternatively, Mrp2 itself may not be involved in GSH transport 
but may regulate an endogenous ATP-independent GSH transporter. Such a 
regulatory mechanism for Mrp2 has been proposed based on results from uptake 
studies with liver canalicular membrane vesicles [2,8,22]. Radiation inactivation of 
canalicular GSH transport has indicated the complexity of low-affinity GSH 
transport, which involves multiple putative transporters including presumably 
Mrp2 [22]. Furthermore, low-affinity GSH uptake into liver canalicular membrane 
vesicles is ds-inhibited by DNP-SG in the absence of ATP but trans-stimulated by 
DNP-SG in the presence of ATP [2,8]. The characteristics of this Mrp2-regulated 
GSH transport, however, are different from our results, because anionic conjugates 
inhibited GSH uptake into Sf9-Mrp2 membrane vesicles in the presence of ATP, 
whereas they did not affect uptake in the absence of ATP.
A recent report by Paulusma et al. is at variance with the hypothesis of Mrp2 
as both an ATP-dependent anionic conjugate transporter and an ATP-independent 
GSH transporter [25]. These authors demonstrated that inhibition of ATP synthesis 
in MRP2-transfected MDCKII cells greatly reduced efflux of both DNP-SG and 
GSH across the apical membrane [7,25]. Nonetheless, a difference in uptake of 
GSH between membrane vesicles of transfected and parental cells either in the 
presence or absence of ATP was undetectable [25]. Similar contradictory results 
obtained with intact cells and isolated membrane vesicles have been reported for 
MRP1. Whereas expression levels of MRP1 correlate with efflux of GSH from 
intact cells [25,26,33], MRP1-mediated uptake of GSH into membrane vesicles 
either in the presence or absence of ATP could not be demonstrated [16,20]. It has 
recently been suggested that MRP1 and MRP2 might mediate GSH efflux from 
intact cells in the form of a short-lived complex with an intracellular compound, 
which is lacking in preparations of membrane vesicles [25,33]. Such a mechanism 
would explain why Mrp2-deficient rats have very low biliary GSH levels, although 
GSH uptake into EHBR canalicular membrane vesicles is intact [8,24]. On the 
other hand, membrane vesicle preparations from various cell lines and tissues may 
be unsuitable to detect GSH uptake because of their mixed orientation and
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possible leakage. Recently, Rebbeor et al. have demonstrated GSH uptake into 
yeast sec6-4 membrane vesicles [27], which are orientated almost exclusively 
inside-out [1]. Uptake of GSH into these vesicles was saturable (Km = 15-20 mM), 
competitively inhibited by DNP-SG (Ki = —0.2 mM), and dependent on ATP. A 
further study identified the yeast cadmium factor 1 (YCF1), a yeast ortholog of 
mammalian MRP1 and MRP2 [17], as the major contributor to ATP-dependent 
GSH transport [28]. However, membrane vesicles from wildtype yeast also show 
low levels of ATP-independent GSH uptake and at present it is unknown whether 
YCF1 or a different transporter is involved [27,28].
The physiological significance of MRP2-mediated GSH secretion into bile and 
urine is not clear. Biliary and urinary GSH may provide protection against 
oxidative damage and, in addition, may be a source for glutamate, glycine and 
cysteine after degradation of GSH by extracellular membrane-bound peptidases 
[23]. Furthermore, urinary GSH may account for detoxification of agents that enter 
the urine directly via glomerular filtration. Besides MRP2, also other transport 
proteins are involved in biliary GSH secretion [3]. In liver canalicular membranes, 
the putative low and high affinity ATP-independent GSH transporters both have an 
estimated molecular weight of — 70 kDa [22]. Although their molecular identity is 
unknown, these transporters might be canalicular isoforms of the 74 kDa 
sinusoidal organic anion transporting polypeptide (Oatp1), which functions as a 
GSH/organic solute exchanger [3].
In this study, we tried to address the mechanism by which GSH affects Mrp2- 
mediated ATP-dependent VBL transport. Possible explanations for the effect of 
GSH are spontaneous formation of a glutathione-S-conjugate, a cotransport 
mechanism or an indirect interaction. So far, conjugates of GSH with vinca 
alkaloids, such as VCR and VBL, have not been demonstrated [4,31]. Furthermore, 
HPLC analysis of the products excreted by MRP1 -transfected SW-1573/S1 cells 
after preloading with VCR only revealed unmodified drugs [33]. Thus, either GSH 
is cotransported with VBL or GSH indirectly stimulates ATP-dependent VBL 
transport. GSH stimulates Mrp2-mediated ATP-dependent VBL transport with an
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apparent half maximum stimulation at —2 mM. A similar value (2.7 mM) was 
found for GSH-stimulated ATP-dependent daunorubicin transport by MRP1 [29]. 
The transport affinity of GSH for MRP2/Mrp2 appears to be 10-fold lower ( — 20 
mM), which is in the same range as reported for YCF1 [25,28]. This suggests that 
VBL enhances the affinity of GSH for Mrp2, but we could not demonstrate that 
VBL induces Mrp2-mediated GSH transport as one would expect for a cotransport 
mechanism. Loe et al. [20] recently have shown both GSH-stimulated VCR and 
VCR-stimulated GSH uptake into membrane vesicles of HeLa cells overexpressing 
human MRP1, suggesting a VCR/GSH cotransport mechanism. VBL also stimulated 
GSH uptake into MRP1 enriched membrane vesicles, although to a lesser degree 
than VCR [20]. With respect to our results, we cannot exclude that it is impossible 
to detect a VBL-dependent stimulation of GSH transport above the background of 
GSH uptake, because of the relatively low affinity and high Vmax of the latter 
process. However, even if VBL does not stimulate GSH transport, we conclude 
from our data that Mrp2-mediated GSH transport does not require the cotransport 
of VBL.
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Summary
p-Aminohippurate (PAH) is widely used as a model substrate to characterize 
organic anion transport in kidney proximal tubules. The carrier responsible for 
uptake of PAH across the basolateral membrane has been cloned and well 
characterized, whereas transporters mediating PAH excretion across the brush- 
border (apical) membrane are still elusive. The multidrug resistance protein 2 
(Mrp2) is an ATP-dependent organic anion transporter expressed in liver, small 
intestine, and at the proximal tubule brush-border membrane. In this study, we 
show that membrane vesicles from Sf9 cells overexpressing rabbit Mrp2 exhibit 
saturable ATP-dependent [14C]PAH uptake (Km = 1.7 ± 0.4 mM, Vmax = 8 .6  ± 1.5 
nmol/mg/5 min). The organic anions leukotriene C4 (K = 1.0 ± 0.4 jM ), estradiol- 
175-D-glucuronide, lucifer yellow, FURA-AM, fluorescein-methotrexate, and 
probenecid inhibit ATP-dependent [14C]PAH uptake. In conclusion, Mrp2 is the 
first renal apical organic anion transporter proven to mediate PAH transport.
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Introduction
The kidney plays an important role in the clearance of endogenous compounds 
and xenobiotics from the body. The proximal tubule is the primary site at the 
nephron where organic anions are taken up from the blood and excreted into 
urine. p-Aminohippurate (PAH) is widely used as a model substrate to investigate 
renal handling of organic anions because of its high renal clearance and low 
susceptibility to metabolism [19]. Uptake of PAH from the blood across the 
basolateral membrane is mediated by the PAH/dicarboxylate exchanger OAT1 
[4,10,23,26,27]. This is a so-called tertiary active process coupled indirectly via 
Na+/dicarboxylate cotransport to the Na+ gradient, which is maintained by the 
Na+/K+ ATPase [18,24]. Studies with isolated membrane vesicles have shown that 
excretion of PAH across the brush-border (apical) membrane involve potential- 
driven facilitated transport as well as an anion exchange mechanism [15,20]. Both 
systems have not yet been identified at the molecular level. The cloned organic 
anion transporters Oatp1 and Oat-k1 , which have been localized to the brush- 
border membrane, do not appear to transport PAH [1,6,14,21].
The multidrug resistance protein 2 (MRP2) is an ATP-dependent organic 
anion transporter located at the apical membrane of hepatocytes, small intestinal 
villi, and renal proximal tubules (refs. [7,22] and van Aubel et al., unpublished). 
Substrates of MRP2 include conjugated organic anions, such as leukotriene C4 
(LTC4), estradiol-175-D-glucuronide (E217SG), and bilirubin-glucuronide, and 
unconjugated organic anions, such as bromosulfophthalein and folates [25]. In this 
study, we investigated whether MRP2 may also mediate ATP-dependent transport 
of PAH. Therefore, we determined uptake of [14C]PAH into membrane vesicles 
from Sf9 cells overexpressing recombinant rabbit Mrp2.
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Experimental procedures
Materials. [14C]PAH (53.1 mCi/mmol) and [6,7-3H]E2175G (55 Ci/mmol) were purchased 
from NEN Life Science Products (Hoofddorp, The Netherlands). Creatine phosphate and 
creatine kinase were purchased from Boehringer Mannheim (Almere, The Netherlands). 
Glass fiber GF/F filters were purchased from Whatmann (Omnilabo International, Breda, 
The Netherlands). All other chemicals were obtained from Sigma (Zwijndrecht, The 
Netherlands).
Sf9-Mrp2 and control cells. Sf9 cells expressing rabbit Mrp2 (Sf9-Mrp2) were generated by 
infection of cells with a recombinant baculovirus encoding Mrp2 as described previously 
[28]. Briefly, Sf9 cells (106/ml) were grown as 100 ml suspension cultures and infected for 
three days at a multiplicity of infection of 1-5 with Mrp2-encoding baculovirus. For control 
experiments, Sf9 cells infected with a baculovirus encoding the 5-subunit of rat H+/K+ 
ATPase were used (Sf9-mock).
Transport studies. Membrane vesicles from Sf9-Mrp2 and control cells were isolated as 
described [28]. Uptake of [14C]PAH (50 jM ) or [3H]E2175G (50 nM) into membrane 
vesicles was performed as described [28]. Briefly, membrane vesicles (40 jg  protein- 
equivalent) were thawed for 1 min at 37 °C  and added to pre-warmed TS-buffer (10 mM 
Tris-Hepes/ 250 mM sucrose pH 7.4) supplemented with an ATP-regeneration mix (4 mM 
ATP, 10 mM MgCl2, 10 mM creatine phosphate, 100 jg/ml creatine kinase) and a labeled 
compound in a final volume of 60 j l .  The reaction mixture was incubated at 37 °C  and at 
indicated times samples were taken from the mixture, diluted in 1 ml ice-cold TS-buffer 
and filtered through Whatman GF/F filters using a filtration device (Millipore Corp., 
Bedford, MA). Filters were washed once with ice-cold 5 ml TS-buffer and dissolved in 
liquid scintillation fluid to determine the radioactivity bound. In control experiments, ATP 
was omitted from the reaction mixtures. Net ATP-dependent transport was calculated by 
subtracting values in the absence of ATP from those in the presence of ATP. 
Measurements were corrected for the amount of ligand bound to the filters (usually < 2%  
of total radioactivity).
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Determination of kinetic parameters. ATP-dependent [14C]PAH uptake into membrane 
vesicles of Sf9-Mrp2 cells could be described as uptake via a Michaelis-Menten process in 
parallel with nonspecific uptake. The Mrp2-mediated component of uptake was defined as 
the difference between ATP-dependent uptake in membrane vesicles of Sf9-Mrp2 and Sf9- 
mock cells. Inhibition of LTC4 against ATP-dependent [14C]PAH uptake was analyzed 
assuming competitive inhibition to a one binding site model. The inhibition constant (Ki) 
was calculated according to the equation:
Ki = IC50/(1 + (S/Km))
where IC50 is the concentration of LTC4 at half maximal inhibition, S is the [14C]PAH 
concentration, and Km is the Michaelis-Menten constant of Mrp2-mediated ATP-dependent 
[14C]PAH uptake. Curve fitting was done by least squares nonlinear regression analysis 
using the GraphPad software (GraphPad Prism version 3.0 for Windows, GraphPad 
Software, San Diego, USA).
Results
We investigated uptake of [14C]PAH into membrane vesicles prepared from Sf9 
cells infected with a baculovirus containing a full-length rabbit mrp2 cDNA (Sf9- 
Mrp2). W e have recently shown that these membrane vesicles contain functional 
Mrp2 as assessed by ATP-dependent uptake of the anionic conjugates [3H]LTC4 
and [3H]E2175G [28]. The time course of [14C]PAH uptake into these vesicles is 
shown in Fig. 1. In the presence of ATP, membrane vesicles from Sf9-Mrp2 cells 
exhibited uptake of [14C]PAH, whereas in the absence of ATP, uptake was 
negligible (Fig. 1A). The non-metabolizable ATP analogue 5'-AMP did not 
stimulate uptake of [14C]PAH (not shown). Membrane vesicles of mock-infected Sf9 
cells (Sf9-mock) exhibited a relatively high basal uptake of [14C]PAH in the 
presence of ATP. Net ATP-dependent [14C]PAH uptake in membrane vesicles of 
Sf9-Mrp2 and Sf9-mock cells was linear with time up to 5 min with initial rates of
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1/[sucrose] (1/M )
Fig. 1. Time course and osmolarity 
dependency of Mrp2-mediated [,4C]PAH 
uptake. Membrane vesicles prepared from 
Sf9-Mrp2 and Sf9-mock cells were incubated 
in TS-buffer with 50 jjM  [14C]PAH at 37 °C  
and samples were taken from the reaction 
mixture for the times indicated.
A, uptake of [14C]PAH into Sf9-Mrp2 
membrane vesicles in the absence (▲) or 
presence (■) of ATP.
B, net ATP-dependent [14C]PAH uptake into 
membrane vesicles of Sf9-mock (□) and Sf9- 
Mrp2 (■) cells. Data are the mean ± S.E. from 
two experiments performed in triplicate.
C, ATP-dependent [14C]PAH uptake into 
membrane vesicles of Sf9-mock (□) and Sf9- 
Mrp2 (■) cells was determined for 5 min in 
the presence of sucrose concentrations 
ranging from 250 mM (isotonic condition) to 
1000 mM. Transport of [14C]PAH was plotted 
against the inverse sucrose concentration in 
the reaction mixture. Linear fitting of the 
obtained data was performed using GraphPad 
Prism version 3.00 for Windows (GraphPad 
Software, San Diego CA, USA). Data are 
mean ± S.D. from one experiment performed 
in triplicate.
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116 ± 20 pmol/mg/5 min and 64 ± 10 pmol/mg/5 min, respectively (Fig. 1B). As 
assessed by uptake studies at increasing extravesicular osmolarities, [14C]PAH 
values represent uptake into the vesicular space of both Sf9-mock and Sf9-Mrp2 
membrane vesicles and little binding (< 2%) was observed (Fig. 1C).
Initial rates of ATP-dependent [14C]PAH uptake in membrane vesicles of Sf9- 
Mrp2 and Sf9-mock cells increased with increasing PAH concentrations (Fig 2A). 
Values obtained using Sf9-Mrp2 membrane vesicles were corrected for basal ATP- 
dependent [14C]PAH uptake as observed in Sf9-mock membrane vesicles and were 
fitted to the Michaelis-Menten equation. Parameter values (mean ± S.E.) obtained 
were a Km of 1.7 ± 0.4 mM and a Vmax of 8 .6  ± 1.5 nmol/mg/5 min for Mrp2- 
mediated ATP-dependent PAH transport (Fig. 2B).
LTC4 is a high-affinity substrate for rat/human Mrp2/MRP2 (Km ~ 1 jM ) [2]. As 
shown in Fig. 3, LTC4 inhibited Mrp2-mediated ATP-dependent [14C]PAH uptake in 
a concentration-dependent manner, and curve fitting gave a Ki value of 1.0 ± 0.4 
jM . At 3 jM , LTC4 inhibited Mrp2-mediated ATP-dependent [14C]PAH uptake to 
basal levels observed in membrane vesicles of Sf9-mock cells.
We further investigated the inhibitory effects of various other organic anions 
on Mrp2-mediated ATP-dependent [14C]PAH uptake (Table 1). For comparison, we 
tested the same compounds for their ability to inhibit ATP-dependent [3H]E217£G 
uptake by Mrp2. E217SG, at a two-fold higher concentration than [14C]PAH, was a 
strong inhibitor of ATP-dependent [14C]PAH uptake (82% inhibition). In contrast, 
[3H]E217£G uptake rates were inhibited for 35% by PAH at a concentration that 
exceeded the [3H]E217£G concentration to four orders of magnitude. Probenecid, 
which is an inhibitor of organic anion transport, inhibited [14C]PAH and 
[3H]E217£G uptake rates to a similar or lower extent than fluorescein-methotrexate.
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[PAH] (|JM)
[PAH] (j M)
Fig. 2. Kinetic analysis of Mrp2-mediated ATP-dependent [,4C]PAH uptake. A, membrane vesicles 
from Sf9-mock (Q  and Sf9-Mrp2 (■) cells were incubated with [14C]PAH at 50-400 jM  for 5 min. 
Lines through the data points are the fitted lines according to Michaelis-Menten kinetics in parallel 
with nonspecific transport. B, corrected Mrp2-specific ATP-dependent [14C]PAH uptake. Data are 
the mean ± S.E. from two experiments performed in triplicate.
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Fig. 3. Effect of LTC4 on ATP- 
dependent [14C]PAH uptake.
Membrane vesicles from Sf9-Mrp2 
cells were incubated with 50 /j M 
[14C]PAH for 5 min in the absence 
or presence of 100, 250, 500, 1000, 
or 3000 nM LTC4. Data are the 
mean ± S.E. from two experiments 
performed in triplicate. Line through 
the data points is the fitted line 
according to a one-site competitive 
model.
0 ' ' 2 3 4
log [LTC4] (nM)
TABLE 1
Effect of various organic anions on ATP-dependent uptake of [14C]PAH and [3H]E2176G into 
Sf9-Mrp2 membrane vesicles
Compound ATP-dependent transport
[14C]PAH [3H]E217gG
% control % control
None (control) 100 100
E217£G (0.1 mM) 18 ± 8 nd
PAH (1 mM) nd 65 ± 9
probenecid (0.1 mM) 90 ± 4a 39 ± 9
FL-MTX (10 yvM) 51 ± 9 38 ± 8
FURA-AM (10 yvM) 75 ± 2 3 ± 1
LY (10 yvM) 79 ± 1 5 ± 2
Membrane vesicles from Sf9-Mrp2 cells were incubated with [14C]PAH (50 j M) or [3H]E2l7fiG (50 
nM) in the absence (control) or presence of the compounds as indicated. Net ATP-dependent 
transport was calculated by subtracting values in the absence of ATP from those in the presence of 
ATP. Transport was expressed as percent of the control uptake. Data are mean (± S.D.) from a 
typical experiment performed in triplicate. All data were significantly different from controls 
(p<0.01; p<0.05a, analysis of variance with Bonferroni's correction). nd, not determined.
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Discussion
The present study demonstrates that the classical model compound for renal 
organic anion secretion, PAH, is a substrate for Mrp2, which is expressed at the 
brush-border membrane of renal proximal tubules. By using membrane vesicles 
from Sf9 cells expressing rabbit Mrp2, we demonstrated that [14C]PAH uptake is 
time- and ATP-dependent. In addition, Mrp2-mediated ATP-dependent [14C]PAH 
uptake was saturable with a Km value of 1.7 ± 0.4 mM. The affinity of PAH for 
Mrp2 is low in comparison with DNP-SG (0.18 jM ), LTC4 (1 jM ), and E217SG (7 
jM ), but higher as compared to reduced glutathione (20 mM) [2,5,16]. 
Furthermore, LTC4 inhibited Mrp2-mediated PAH transport with a Ki value of 1.0 
± 0.4 jM , which is consistent with a Km of approximately 1 jM  determined for 
rat/human Mrp2/MRP2 [2]. In a preliminary report, it has been shown that 
membrane vesicles from human MRP7-transfected HeLa cells also exhibit ATP- 
dependent PAH transport [8]. In contrast to Mrp2, Mrp1 is not expressed in 
proximal tubules but located at the basolateral membrane of cells of renal distal 
tubules [17,29].
Little is known about the molecular identity of the pathways for organic anion 
transport at the brush-border membrane. Studies in brush-border membrane 
vesicles using PAH as a substrate, have indicated the presence of at least two 
transport systems, i.e. an anion exchange mechanism and potential-driven 
facilitated diffusion [15,20]. ATP-dependent PAH uptake has never been 
demonstrated in these vesicles. This may be explained by the inaccessibility of the 
ATP-binding site because of the almost complete rightside-out orientation of brush- 
border membrane vesicles from proximal tubular cells [3]. In intact killifish renal 
proximal tubules an energy-dependent efflux pathway has been characterized for 
the organic anions FL-MTX and LY [11,12]. Luminal efflux of FL-MTX and LY was 
inhibited by the Mrp2 substrates LTC4 and DNP-SG in a concentration-dependent 
manner [11,12]. Furthermore, immunohistochemistry with an antibody directed 
against rabbit Mrp2 revealed staining of the brush-border membrane [13]. This
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indicates that an ortholog of rabbit Mrp2 is involved in luminal excretion of FL- 
MTX and LY in killifish proximal tubules. This is further corroborated by our 
finding that FL-MTX and LY appeared to be good inhibitors of Mrp2-mediated ATP- 
dependent transport of PAH and E217SG.
The contribution of Mrp2 to overall urinary excretion of PAH is still elusive. 
Efflux of FL-MTX from killifish proximal tubules is marginally inhibited by PAH 
[12]. However, this may reflect a difference in affinity, since FL-MTX appeared to 
be a strong inhibitor of Mrp2-mediated ATP-dependent PAH transport at a 
concentration 5-fold lower than tracer PAH, suggesting that FL-MTX is a high- 
affinity substrate unlike PAH. In contrast to FL-MTX, efflux of LY is almost 
completely inhibited by PAH but only partly by LTC4, which may be explained by 
involvement of multiple organic anion transporters [11]. Efflux of the mercapturic 
acid derivative of monochlorobimane (Nac-MCB-Cys) from killifish proximal 
tubules is also inhibited by LTC4 and PAH [11]. However, it is not yet known 
whether Nac-MCB-Cys is also a substrate for Mrp2 alongside S-(MCB)-glutathione 
[9].
Previous studies with isolated renal membrane vesicles have shown the 
existence of two ATP-independent low-affinity (Km 5-7 mM) pathways for the efflux 
of PAH across the brush-border membrane [15,20]. The present results indicate 
that Mrp2 may be a third low-affinity pathway mediating the ATP-dependent renal 
excretion of PAH. Whether Mrp2 contributes significantly to urinary PAH 
excretion will depend on its density at the brush-border membrane as compared to 
other systems.
Acknowledgments
We thank J.B. Koenderink (Dept. Biochemistry, University of Nijmegen) for expert 
technical assistance.
116
ATP-Dependent PAH Transport by Mrp2
References
1. Bergwerk, A.J., X. Shi, A.C. Ford, N. Kanai, E. Jacquemin, R.D. Burk, S. Bai, P.M. Novikoff, B. Stieger, P.J. Meier,
V.L. Schuster, and A.W . Wolkoff. (1996). Immunologic distribution of an organic anion transport protein in rat 
liver and kidney. Am. J. Physiol. 271: G231-G238.
2. Cui, Y., J. König, U. Buchholz, H. Spring, I. Leier, and D. Keppler. (1999). Drug resistance and ATP-dependent
conjugate transport mediated by the apical multidrug resistance protein, MRP2, permanently expressed in human 
and canine cells. Mol. Pharmacol. 55: 929-937.
3. Haase, W ., A. Schafer, H. Murer, and R. Kinne. (1978). Studies on the orientation of brush-border membrane
vesicles. Biochem. J. 172: 57-62.
4. Hosoyamada, M., T. Sekine, Y. Kanai, and H. Endou. (1999). Molecular cloning and functional expression of a
multispecific organic anion transporter from human kidney. Am. J. Physiol. 276: F122-F128.
5. Ito, K., H. Suzuki, T. Hirohashi, K. Kume , T. Shimizu, and Y. Sugiyama. (1998). Functional analysis of a 
canalicular multispecific organic anion transporter cloned from rat liver. J. Biol. Chem. 273: 1684-1688.
6. Kanai, N., R. Lu, Y. Bao, A .W . Wolkoff, and V.L. Schuster. (1996). Transient expression of oatp organic anion
transporter in mammalian cells: identification of candidate substrates. Am. J. Physiol. 270: F319-F325.
7. Keppler, D. and J. König. (1997). Expression and localisation of the conjugate export pump encoded by the MRP2
(cMRP/cMOAT) gene in liver. FASEB J. 11: 509-516.
8. Keppler, D., J. König, T.P. Schaub, and I. Leier. Molecular basis of ATP-dependent transport of anionic conjugates
in kidney and liver. In: Renal and hepatic transport - Similarities and Differences, edited by C. Fleck, W . Klinger, 
and D. Muller. Halle: Nova acta leopoldina, (1998). p. 213-221.
9. Kinoshita, S., H. Suzuki, K. Ito, K. Kume , T. Shimizu, and Y. Sugiyama. (1998). Transfected rat cM O AT is 
functionally expressed on the apical membrane in Madin-Darby canine kidney (MDCK) cells. Pharm. Res. 15: 
1851-1856.
10. Lu, R., B.S. Chan, and V.L. Schuster. (1999). Cloning of the human kidney PAH transporter: narrow substrate 
specificity and regulation by protein kinase C. Am. J. Physiol. 276: F295-F303.
11. Masereeuw, R., M.M. Moons, B.H. Toomey, F.G.M. Russel, and D.S. Miller. (1999). Active Lucifer Yellow 
secretion in renal proximal tubule: evidence for organic anion transport system crossover. J. Pharmacol. Exp. 
Ther. 289: 1104-1111.
12. Masereeuw, R., F.G.M. Russel, and D.S. Miller. (1996). Multiple pathways of organic anion secretion in renal 
proximal tubule revealed by confocal microscopy. Am. J. Physiol. 271: F1173-F1182.
13. Masereeuw, R., S. A. Terlouw, R. A. M. H. van Aubel, F. G. M. Russel, and D. S. Miller. (2000). Endothelin B 
receptor-mediated regulation of ATP-driven drug secretion in renal proximal tubule. Mol. Pharmacol., in press.
14. Masuda, S., H. Saito, H. Nonoguchi, K. Tomita, and K.-I. Inui. (1997). mRNA distribution and membrane 
localization of the OAT-K1 organic anion transporter in rat renal tubules. FEBS Lett. 407: 127-131.
15. Ohoka, K., M. Takano, T. Okano, S. Maeda , K. Inui, and R. Hori. (1993). p-Aminohippurate transport in rat 
renal brush-border membranes: a potential-sensitive transport system and an anion exchanger. Biol. Pharm. Bull. 
16: 395-401.
16. Paulusma, C.C., M. van Geer, R. Evers, M. Heijn, R. Ottenhoff, P. Borst, and R.P.J. Oude Elferink. (1999). 
Canalicular multispecific organic anion transporter/multidrug resistance protein 2 mediates low-affinity transport 
of reduced glutathione. Biochem. J. 338: 393-401.
17. Peng, K.-C., F. Cluzeaud, M. Bens, J.-P. Duong van Huyen, M.A. Wioland, R. Lacave, and A. Vandewalle. 
(1999). Tissue and cell distribution of the multidrug resistance-associated protein (MRP) on mouse intestine and 
kidney. J. Histochem. Cytochem. 47: 757-767.
18. Pritchard, J.B. (1988). Coupled transport of p-aminohippurate by rat kidney basolateral membrane vesicles. Am. 
J. Physiol. 255: F597-F604.
19. Pritchard, J.B. and D.S. Miller. (1993). Mechanisms mediating renal secretion of organic anions and cations. 
Physiol. Rev. 73: 765-796.
117
Chapter Five
20. Russel, F.G.M., P.E. van der Linden, W .G . Vermeulen, M. Heijn, C.H. van Os, and C.A. van Ginneken. (1988). 
Na+ and H + gradient-dependent transport of p-aminohippurate in membrane vesicles from dog kidney cortex. 
Biochem. Pharmacol. 37: 2639-2649.
21. Saito, H., S. Masuda, and K.-I. Inui. (1996). Cloning and functional characterization of a novel rat organic anion 
transporter mediating basolateral uptake of methotrexate in the kidney. J. Biol. Chem. 271: 20719-20725.
22. Schaub, T.P., J. Kartenbeck, J. König, H. Spring, J. Dorsam, G. Staehler, S. Storkel, W .F. Thon, and D. Keppler.
(1999). Expression of the MRP2 gene-encoded conjugate export pump in human kidney proximal tubules and in 
renal cell carcinoma. J. Am. Soc. Nephrol. 10: 1159-1169.
23. Sekine, T., N. Watanabe, M. Hosoyamada, Y. Kanai, and H. Endou. (1997). Expression cloning and 
characterization of a novel multispecific organic anion transporter. J. Biol. Chem. 272: 18526-18529.
24. Shimada, H., B. Moewes, and G. Burckhardt. (1987). Indirect coupling to Na+ of p-aminohippurate acid uptake 
into rat renal basolateral membrane vesicles. Am. J. Physiol. 253: F795-F801.
25. Suzuki, H. and Y. Sugiyama. (1998). Excretion of GSSG and glutathione conjugates mediated by MRP1 and 
cMOAT/MRP2. Semin. Liver. Dis. 18: 359-376.
26. Sweet, D.H., N.A. Wolff, and J.B. Pritchard. (1997). Expression cloning and characterization of ROAT1. The 
basolateral organic anion transporter in rat kidney. J. Biol. Chem. 272: 30088-30095.
27. Uwai, Y., M. Okuda, K. Takami, Y. Hashimoto, and K.-I. Inui. (1998). Functional characterization of the rat 
multispecific organic anion transporter OAT1 mediating basolateral uptake of anionic drugs in the kidney. FEBS 
Lett. 438: 321-324.
28. van Aubel, R.A.M.H., M.A. van Kuijck, J.B. Koenderink, P.M.T. Deen, C.H. van Os, and F.G.M. Russel. (1998). 
Adenosine triphosphate-dependent transport of anionic conjugates by the rabbit multidrug resistance-associated 
protein Mrp2 expressed in insect cells. Mol. Pharmacol. 53: 1062-1067.
29. Wijnholds, J., G.L. Scheffer, M. vanderValk, P. vanderValk, J.H. Beijnen, R.J. Scheper, and P. Borst. (1998). 
Multidrug resistance protein 1 protects the oropharyngeal mucosal layer and the testicular tubules against drug- 
induced damage. J. Exp. Med. 188: 797-808.
118
Chapter 6
Summary,
General Conclusions and 
Future Perspectives
119
12G
Summary, General Conclusions & Future Perspectives
Summary
Renal organic anion transport systems play an important role in the elimination of 
endogenous waste products and xenobiotics, many of which are potentially 
harmful to the body. In the kidney, the proximal tubule is the site where organic 
anions are taken up from the blood across the basolateral membrane. This uptake 
involves an active transport mechanism, because organic anions are transported 
against a steep electrochemical gradient. Therefore, uptake is the rate-limiting step 
in excretion of organic anions into the urine. Much attention has been paid to the 
organic anion uptake process, using p-aminohippurate (PAH) as a model substrate 
in studies with isolated proximal tubules, basolateral membrane vesicles, or 
perfused kidney. On the other hand, the transport systems mediating efflux of 
organic anions across the brush-border membrane have been studied less well. 
This is in contrast with the field of liver research, in which organic anion 
transporters involved in biliary efflux of bile acid and non-bile acid organic anions 
across the canalicular (apical) membrane have been well characterized. In the 
hepatocyte, excretion of organic anions is directed against a very high 
concentration gradient maintained in bile and therefore requires active transport 
systems. Studies with isolated canalicular membrane vesicles, cultured 
hepatocytes, and perfused liver, have indicated that biliary excretion of non-bile 
acid organic anions is mediated by an ATP-dependent transport system designated 
as the canalicular multispecific organic anion transport (cMOAT) system. Without 
knowing its molecular identity, substrate characteristics of cMOAT have been 
investigated in comparative transport studies with livers from wildtype rats and 
two natural mutant rat strains (GY/TR- and EHBR) defective in cMOAT. These 
mutant rats develop mild conjugated hyperbilirubinemia or congenital jaundice as 
a consequence of defective cMOAT activity and hepatic accumulation of bilirubin­
glucuronides.
The cloning of the gene encoding the protein responsible for cMOAT was 
initiated from a different field of research. Resistance of cancer cells to
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chemotherapeutic drugs is a major problem in treating patients with 
chemotherapy. The phenotype of multidrug resistance (MDR) is associated with 
overexpression of the ATP-binding cassette (ABC) family members (MDR1-gene 
encoded) P-glycoprotein (Pgp) and multidrug resistance protein 1 (MRP1). 
Overexpression of either Pgp or MRP1 in drug-sensitive cells results in resistance 
to various chemotherapeutics. The link with cMOAT was made when, virtually at 
the same time, two groups reported evidence that membrane vesicles from human 
MRPI-transfected cells exhibit ATP-dependent uptake of anionic conjugates, such 
as S-(dinitrophenyl)-glutathione and leukotriene C4 (LTC4) (Müller et al., 1994, 
Proc. Natl. Acad. Sci. 91, 13033; Leier et al., 1994, J. Biol. Chem. 269, 27807). 
Since biliary excretion of these compounds is markedly decreased in GY/TR" and 
EHBR rats, but mrpl gene expression in wildtype rat liver is very low, cMoat was 
proposed as a homolog of rat Mrp1. Indeed, three groups reported the cloning of 
cMoat as a novel member of the ABC-family with highest identity to MRP1 
(Büchler et al., 1996, J. Biol. Chem. 271, 15091; Paulusma et al., 1996, Science 
271, 1126; Ito et al., 1997, Am. J. Physiol. 272, G16). In livers of GY/TR- and 
EHBR, cMoat appeared to be absent from the canalicular membrane and sequence 
analysis revealed a mutation causing a premature termination of the cmoat gene 
product. Because of its structural and functional homology to MRP1 and the 
subsequent cloning of several other human MRP-homologs (MRP3-MRP6), 
cMOAT was renamed MRP2. Besides in liver, MRP2 is also expressed in the 
kidney and small intestine. In the kidney, MRP2 is located to the brush-border 
membrane of renal proximal tubules. Membrane vesicles of the brush-border 
membrane, however, are exclusively orientated right-side-out with the binding site 
for ATP directed intravesicularly, which explains why ATP-dependent organic 
anion transport activity has never been found in this preparation.
In the investigation described in this thesis, we functionally expressed rabbit 
Mrp2 in Sf9 cells to characterize its transport properties and to use this model 
system to identify putative substrates, with emphasis on compounds that are 
excreted by the kidney. In chapter 1, we give a concise overview of the properties
122
Summary, General Conclusions & Future Perspectives
of organic anion transporters located at the basolateral and brush-border 
membrane of the renal proximal tubule. Various transport systems have been 
characterized at the physiological level. Some of these transport systems have also 
been cloned, such as the PAH/dicarboxylate exchanger Oat1, the anion/sulfate 
exchanger Sat1, the peptide transporters PEPT1 and 2, and the nucleoside 
transporters CNT1 and 2. For others, such as Mrp1, Mrp2, Oatpl, Oat-k1, and 
Oat-k2, a function in the kidney remains to be established. Finally, the homologs 
Oat2/-3, Oatp3, and MRP3-MRP6 have been cloned but their subcellular 
localization in the kidney is still elusive.
In chapter 2, we investigated whether rabbit Mrp2 functions as an ATP- 
dependent organic anion transporter. Therefore, we overexpressed rabbit Mrp2 in 
Spodoptera frugiperda (Sf9) cells using a baculovirus expression system. In 
membranes of Sf9 cells, Mrp2 was detected as an underglycosylated protein of 
~180 kDa. The expression level of Mrp2 in membranes of Sf9 cells was — 4-fold 
higher as compared to its expression level in kidney and liver membranes. By 
using a rapid filtration technique, Mrp2-mediated transport activity was assessed in 
isolated membrane vesicles supplemented with an ATP-regenerated system. 
Estradiol-17S-D-[3H]-glucuronide ([3H]E217SG) and [3H]LTC4 were taken up ATP- 
dependently into membrane vesicles of Sf9-Mrp2 cells but not into control vesicles 
from mock-infected cells. Evidence was provided for actual uptake of [3H]E217SG 
into the vesicles rather than binding. Furthermore, Mrp2-mediated [3H]E217SG 
uptake was saturable for the ATP concentration (Km —0.6 mM). Several 
compounds (LTC4, MK571, cyclosporin A, methotrexate, fluorescein-methotrexate, 
phenolphthalein glucuronide) inhibited Mrp2-mediated ATP-dependent 
[3H]E217SG uptake, whereas others had no effect (a-naphthyl-S-D-glucuronide, 
p-nitrophenyl-S-D-glucuronide, fluorescein).
In the initial cloning paper [van Kuijck MA, van Aubel RAMH, Busch AE, Lang 
F, Russel FGM, Bindels RJM, van Os CH, Deen PMT (1996), Proc. Natl. Acad. Sci. 
93, 5401], we reported localization of Mrp2 to the basolateral membrane of rabbit 
renal distal tubules, although others have shown that in rat kidney, Mrp2
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expression is confined to the apical membrane of the proximal tubule. In chapter 
3, we reanalyzed the subcellular localization of rabbit Mrp2 with a novel 
polyclonal antibody generated in guinea pigs. Mrp2 was detected in Sf9 cells 
infected with an Mrp2-encoding baculovirus, as well as in kidney, liver and small 
intestine. Other tissues, such as lung, heart, colon, and erythrocytes, in which 
various MRP-homologs are expressed, were negative. In rabbit kidney and liver, 
Mrp2 was located to the apical membrane of proximal tubules and hepatocytes. In 
addition, Mrp2 was localized at the brush-border membrane of intestinal villi, 
whereas crypts were negative.
Overexpression of human MRP2 in drug-sensitive cells results in resistance to 
various chemotherapeutic (cationic) drugs, in a manner similar to human MRP1. 
Studies with membrane vesicles have indicated that MRP1 mediates ATP- 
dependent transport of the vinca alkaloid vincristine only in the presence of 
physiological concentrations ( — 5 mM) of reduced glutathione (GSH). 
Furthermore, comparative studies with wildtype and GY/TR" livers have suggested 
that rat Mrp2 transports GSH itself. In chapter 4, we investigated whether rabbit 
Mrp2 is able to transport the vinca alkaloid vinblastine (VBL) with emphasis on the 
role of GSH. Membrane vesicles of Sf9-Mrp2 cells exhibited ATP-dependent 
uptake of [3H]VBL only in the presence of GSH or S-methyl-GSH but not 
glucuronate. Uptake was osmotically sensitive and saturable for VBL (Km — 1.5 jM  
at 5 mM GSH) and GSH (half-maximum stimulation of ATP-dependent VBL uptake 
at —2 mM). Furthermore, the low inhibitory effect of VBL on Mrp2-mediated ATP- 
dependent [3H]LTC4 uptake was potentiated by GSH in a concentration-dependent 
fashion. Sf9-Mrp2 membrane vesicles also exhibited osmotic-dependent uptake of 
[3H]GSH. Uptake of [3H]GSH was independent of ATP and inhibited by LTC4, 
E217SG, and MK571, but only in the presence of ATP. Although GSH stimulated 
Mrp2-mediated [3H]VBL uptake, Mrp2-mediated [3H]GSH uptake was not affected 
by VBL.
In view of a putative function for Mrp2 in the kidney, we investigated whether 
the prototypic renal organic anion PAH is a substrate for Mrp2 (chapter 5).
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Membrane vesicles of Sf9-Mrp2 cells exhibited ATP-dependent uptake of 
[14C]PAH. Initial uptake rates in Sf9-Mrp2 membrane vesicles were —2-fold 
increased as compared to rates in membrane vesicles from mock-infected cells. 
Mrp2-mediated ATP-dependent [14C]PAH uptake was saturable (Km —2 mM) and 
susceptible to inhibition by LTC4 with a Ki value of —1 jM , which is in close 
proximity with its Km value. Mrp2-mediated ATP-dependent uptake of [14C]PAH 
was strongly inhibited by E217SG, whereas PAH inhibited ATP-dependent 
[3H]E217SG uptake only modestly. Fluorescein-methotrexate, lucifer yellow, 
FURA-AM, and probenecid also inhibited ATP-dependent uptake of [14C]PAH. 
These results indicate that Mrp2 mediates ATP-dependent PAH transport and 
might contribute to the renal excretion of PAH.
General conclusions & future perspectives
A prerequisite of this thesis was to overexpress rabbit Mrp2 in a cell system for 
functional studies. This appeared to be easier said than done, and took much 
longer than anticipated. Initial transfection experiments were performed with 
various cell lines, including MDCK cells. Throughout culturing, selected clones 
started to detach from the culture dish. W e hypothesized that overexpression of 
Mrp2 might result in a substantial loss of an essential compound from these cells. 
Looking back, GSH might have been this compound. Subsequently, we moved 
from constitutive expression to inducible expression using the tetracycline­
regulatory expression system. Indeed, we obtained several MDCK clones with 
tetracyclin-inducable expression of mrp2 mRNA, but when clones were cultured 
for longer than 48 hours, mRNA dropped to undetectable levels (R.A.M.H. van 
Aubel, not shown). Furthermore, immunoblot analysis did not show any 
expression of Mrp2. We finally sought for an alternative approach and came across 
the baculovirus expression system, which turned out to be successful. This system 
is nowadays easy to handle and does no longer require extensive purification of
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the virus, since the viral genome with the cDNA of interest is isolated from a 
purified E. coli clone. In insect (Sf9) cells infected with a recombinant baculovirus, 
Mrp2 was expressed at high levels. The advantage of this system is the possibility 
of culturing large volumes of infected Sf9 cells necessary for isolation of 
membrane vesicles. A disadvantage, however, is that expression levels of Mrp2 
may vary among different cultures, but this is not different from any other transient 
expression system. Nonetheless, a cell line stably transfected with an mrp2 cDNA 
is desirable.
What have we learned from the studies in this thesis? First of all, we obtained 
conclusive evidence in chapter 2 that our rabbit clone represents the true rabbit 
ortholog of rat Mrp2. Additional transport studies in membrane vesicles will 
answer the question whether the putative substrates fluorescein-methotrexate, 
lucifer yellow, and phenolphthalein glucuronide indeed are transported by Mrp2. 
Coinciding with the results in chapter 2, we show in chapter 3 that like rat Mrp2, 
rabbit Mrp2 is expressed at the apical membrane of hepatocytes and renal 
proximal tubular cells. The finding that Mrp2 is also present in the apical 
membrane of small intestinal villi not only suggests that Mrp2 can transport 
compounds into the intestinal lumen, but can also form a barrier for absorption of 
compounds. In chapter 4, we show that Mrp2 requires GSH for ATP-dependent 
transport of the cationic drug VBL. A proposed mechanism for GSH on Mrp2- 
mediated VBL transport is cotransport of the two compounds. However, such a 
mechanism is not supported by the finding that VBL did not affect GSH uptake 
into Sf9-Mrp2 membrane vesicles. On the other hand, it cannot be excluded that 
stimulation by VBL is undetectable above background of GSH uptake. At this 
stage, the role of GSH on drug transport by MRP2 (and MRP1) is far from being 
resolved. Perhaps, reconstitution of MRP2 into planar lipid bilayers might give 
more insight into this mechanism. Finally, in chapter 5, PAH was quite 
surprisingly identified as an Mrp2 substrate. The question remains whether Mrp2 
plays an important role in the renal excretion of PAH. Therefore, comparative
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studies with wildtype and GY/TR- rats need to be further expanded and the 
involvement of other apical organic anion transporters should be examined.
An important part in the study of Mrp2 is its ATPase activity and the effect of 
anionic and cationic drugs. In a preliminary study, E217SG-induced ATPase 
activity was found in alkaline-stripped membranes of Sf9 cells expressing Mrp2 
(R.A.M.H. van Aubel, not shown). Unfortunately, this result was difficult to 
reproduce for reasons yet unknown and therefore optimizing the purification of 
Mrp2 from crude Sf9 membranes will be necessary. In this thesis, we 
characterized the transport activities of wildtype Mrp2. In future, it will be 
interesting to investigate how truncation of the amino terminus, which is the site 
involved in transport of (at least) LTC4, affects Mrp2 ATPase activity. Furthermore, 
how does truncation of Mrp2 affects GSH transport and GSH-stimulated ATP- 
dependent vinblastine transport? Solving these questions will enhance our insight 
in the transport activities of Mrp2.
The specific polyclonal antibodies described in chapter 2 (k51mrp2) and 3 
(GP8) enable future investigations on the effect of various pathophysiological 
conditions (ischaemia, drug-induced toxicity) on the expression level of Mrp2 in 
the kidney. In parallel, the response of the GY/TR- kidney to such conditions can 
be investigated. Despite the availability of the GY/TR- rat, it might be desirable to 
obtain mice homozygous for a disrupted mrp2 gene, since long-term breeding of 
the mutant rats might have resulted in acquired compensatory mechanisms. 
Second, such an mrp2 knock-out mouse could be cross-breeded with, for example, 
mdr1a (-/-) mdr1b (-/-) double-knockouts, which are homozygous for disrupted 
genes encoding Pgp drug-efflux pumps. Like Mrp2, Pgps are confined to the apical 
membrane of hepatocytes (Mdr1a/b), renal proximal tubules (Mdr1a/b), and small 
intestinal villi (Mdr1a). An mdr1a (-/-) mdr1b (-/-) mrp2 (-/-) triple knockout mouse 
therefore should contribute to the knowledge of these drug transporters in the 
renal and intestinal excretion of xenobiotics.
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Samenvatting
Een belangrijke functie van de nier is het uitscheiden van lichaamseigen en 
lichaamsvreemde stoffen met de urine. De nier functioneert op de eerste plaats als 
een filter, maar beschikt daarnaast over zogenaamde transporters of 
transportsystemen, die in het algemeen specifiek zijn voor anionische (negatief- 
geladen) of kationische (positief-geladen) stoffen. In het eerste (proximale) deel van 
de niertubuli (nierbuisjes), waarvan er ongeveer één miljoen per menselijke nier 
aanwezig zijn, worden anionische en kationische stoffen uit het bloed in de 
tubuluscellen opgenomen en vervolgens uitgescheiden naar het lumen waarin 
zich de voorurine bevindt. Anionische stoffen worden via een zogenaamd actief 
transportsysteem vanuit het bloed, door de celmembraan, opgenomen in de 
proximale tubuluscellen. Daar de cel van binnen negatiever geladen is dan 
erbuiten, moeten anionische stoffen opgenomen worden tegen een 
electrochemische gradient. Aangezien een dergelijk transport energie vereist, 
wordt van een actief transportsysteem gesproken. In het onderzoek van de 
afgelopen 20 jaar heeft vooral dit opnamesysteem centraal gestaan, waarbij de 
anionische verbinding para-aminohippuraat (PAH) als modelstof is gebruikt. Veel 
minder onderzoek is verricht naar het transport vanuit de tubuluscel, via de 
luminale of apicale membraan, naar de voorurine. Daarentegen is er de laatste 
jaren wel veel bekend geworden over een organisch-aniontransportsysteem dat 
zich in de apicale (of canaliculaire) membraan van de levercel bevindt. Dit 
transportsysteem, canaliculaire multispecifieke organisch-aniontransporter 
(cMOAT) genaamd, bewerkstelligt het actieve (ATP-afhankelijke) transport van 
anionische stoffen van de levercel naar de gal. In de rat is cMOAT uitvoerig 
bestudeerd, mede door het bestaan van twee bijzondere rattenstammen met een 
defect in cMOAT. Deze ratten hopen in de lever het glucuronideconjugaat van de 
galkleurstof bilirubine op, een stof die in gezonde ratten goed getransporteerd 
wordt door cMOAT.
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Het erfelijke materiaal (gen) waarin de gegevens zijn opgeslagen voor het cMOAT- 
eiwit, is ontdekt naar aanleiding van resultaten uit kankeronderzoek. Een groot 
probleem bij de behandeling van tumoren met chemotherapie is het op den duur 
resistent worden van de tumor tegen de gebruikte cytostatica. Anders gezegd, de 
tumor heeft geen last meer van de aanwezigheid van deze celdodende stof en kan 
dus verder groeien en uitzaaien. Deze resistentie wordt ondermeer veroorzaakt 
doordat veel tumoren gedurende de behandeling een transportsysteem aanmaken 
dat de cytostatica de tumorcel uitpompt. Tot nu toe zijn twee van deze 
transportsystemen geïdentificeerd, P-glycoproteïne (Pgp) en multidrug-resistance- 
protein (MRP) genaamd. Opmerkelijk was dat MRP niet alleen cytostatica 
(voornamelijk kationische verbindingen) transporteert maar, vergelijkbaar met 
cMOAT, vooral ook anionische verbindingen. Met de kennis over het MRP-gen uit 
de mens, heeft men vervolgens het cmoat/cMOAT-gen geïsoleerd uit 
respectievelijk de rat en de mens. Aangezien cMOAT en MRP erg veel op elkaar 
lijken en aangezien er bovendien nieuwe MRP-genen (MRP3 t/m MRP6) zijn 
gevonden, worden MRP en cMOAT nu respectievelijk, MRP1 en MRP2 genoemd. 
Met de isolatie van het MRP2-gen kon worden aangetoond dat dit 
transportsysteem niet alleen aanwezig is in de apicale membraan van de levercel 
maar ook de proximale niertubuluscel.
In 1995 werd op de afdeling Celfysiologie in samenwerking met de afdeling 
Farmacologie een konijnengen gevonden dat grote overeenkomst vertoonde met 
het mrp2-gen uit de rat. In dit proefschrift hebben we allereerst een celsysteem 
ontwikkeld om de transportkarakteristieken van het konijnen-Mrp2 te onderzoeken 
om vervolgens met dit systeem een mogelijke rol te bepalen voor Mrp2 in de nier. 
Hieronder volgt een uiteenzetting van de inhoud van de afzonderlijke 
hoofdstukken. Na een algemene inleiding over transportsystemen in de nier voor 
anionische verbindingen in hoofdstuk 1, beschrijven we in hoofdstuk 2 de 
ontwikkeling van het celsysteem waarmee Mrp2 is bestudeerd. Om dit celsysteem 
te verkrijgen hebben we gekweekte cellen afkomstig van ovariumweefsel van de 
mot (Spodoptera frugiperda- ofwel Sf9-cellen), zodanig genetisch gemodificeerd
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dat ze konijnen-Mrp2 produceren. Daarvoor zijn deze cellen geïnfecteerd met een 
baculovirus waarin het mrp2-gen is aangebracht. Wanneer het virus de cel is 
binnengedrongen, wordt het ontmanteld en komt het mrp2-gen beschikbaar om in 
de cel te dienen als matrijs voor de synthese van het Mrp2-eiwit. In hoofdstuk 2 
laten we zien dat het bereikte expressieniveau van Mrp2 in de baculovirus- 
geïnfecteerde Sf9-cellen ongeveer 4-maal hoger was dan het expressieniveau in 
levercellen en proximale niertubuli. Voor transportstudies hebben we gebruik 
gemaakt van een uit de geïnfecteerde cellen geïsoleerde (Mrp2-bevattende) 
membraanfractie, de zogenaamde membraanvesicles. Ter controle hebben we 
altijd membraanvesicles uit 'Mrp2-loze' Sf9-cellen gebruikt. Bovendien voegden 
we ATP aan de membraanvesicles toe, aangevuld met een zogenaamd ATP- 
regenerend systeem dat het door Mrp2-verbruikte ATP opnieuw synthetiseert. We 
hebben laten zien dat konijnen-Mrp2 de twee lichaamseigen anionische stoffen 
leukotrieen-C4 (LTC4) en estradiol-17-S-D-glucuronide (E2I 7SG) ATP-afhankelijk 
transporteert. Bij een ATP-concentratie van ongeveer 0.6 mM was het Mrp2- 
gemedieerde transport van E2I 7SG half-maximaal. Tenslotte hebben we laten zien 
dat het ATP-afhankelijke E2I 7SG- transport geremd kon worden door LTC4, 
MK571, cyclosporine A, methotrexaat (MTX), fluoresceïne-methotrexaat (FL-MTX) 
en het glucuronideconjugaat van fenolftaleïne. Daarentegen hadden fluoresceïne 
(FL) en het glucuronideconjugaat van naftol en nitrofenol geen effect. In hoofdstuk 
3 laten we de lokalisatie zien van Mrp2 in de nier, lever en dunne darm van het 
konijn. Daartoe hebben we plakjes (coupes) van deze weefsels bekeken na 
behandeling met een antilichaam, specifiek gericht tegen Mrp2. We laten niet 
alleen de lokalisering van Mrp2 zien in de apicale membraan van levercellen en 
proximale tubuluscellen, maar ook in de top van de vlokken van de dunne darm. 
In hoofdstuk 4 hebben we onderzocht of konijnen-Mrp2, in analogie met MRP1, 
het cytostaticum vinblastine kan transporteren. Door gebruik te maken van de 
eerdergenoemde geïsoleerde membraanvesicles, werd duidelijk dat Mrp2 
vinblastine alléén transporteert in aanwezigheid van gereduceerd glutathion 
(GSH), een belangrijk bestanddeel van elke cel. Andere stoffen, zoals S-methyl-
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GSH en glucuronaat, konden de rol van GSH niet overnemen. Half-maximaal 
Mrp2-gemedieerd transport van vinblastine werd bereikt bij een GSH-concentratie 
van ongeveer 2 mM. Bij een vinblastineconcentratie van 1.5 ¡j M (in aanwezigheid 
van 5 mM GSH) was het Mrp2-gemedieerde vinblastinetransport half-maximaal. 
Terwijl GSH kennelijk essentieel is voor Mrp2-gemedieerd vinblastinetransport, 
bleek vinblastine niet noodzakelijk te zijn voor Mrp2-gemedieerd GSH-transport. 
Bovendien werd GSH, in tegenstelling tot vinblastine, ATP-onafhankelijk 
getransporteerd door Mrp2. Het passieve Mrp2-gemedieerde GSH-transport kon 
echter alléén geremd worden door MK571 en de Mrp2-substraten, LTC4 en 
E217SG, in de aanwezigheid van ATP. In hoofdstuk 5 is tenslotte aangetoond dat 
Mrp2 de modelverbinding PAH op een ATP-afhankelijke wijze transporteert. Dit 
suggereert een rol voor Mrp2 in de renale uitscheiding van deze stof. Bij een 
concentratie van ongeveer 2 mM was het Mrp2-gemedieerde transport van PAH 
half-maximaal. Opvallend was dat de membraanvesicles zonder Mrp2 ook een 
behoorlijk ATP-afhankelijk PAH-transport vertonen. De aanwezigheid van Mrp2 
zorgde uiteindelijk maar voor een verdubbeling van de initiële transportsnelheid. 
Terwijl E217SG een sterke remmer was van het Mrp2-gemedieerde PAH-transport, 
bleek PAH een zwakke remmer van Mrp2-gemedieerd E217£G-transport te zijn.
Conclusies
Wat zijn nu de belangrijkste conclusies die we uit dit proefschrift kunnen trekken? 
Op de eerste plaats is aangetoond dat het product van het geïsoleerde konijnengen 
inderdaad een transporteiwit is, identiek aan Mrp2 van de rat (Hoofdstukken 2 en 
4). We hebben een celsysteem (Sf9) ontwikkeld dat op zichzelf niet nieuw is, maar 
wel door ons als eerste is gebruikt voor het karakteriseren van Mrp2. Het 
celsysteem, zoals beschreven in dit proefschrift, kan uiteindelijk dienen voor de 
screening van een hele reeks stoffen met als doel te bepalen of deze via Mrp2 
getransporteerd worden. Met deze benadering hebben we laten zien dat de
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modelverbinding PAH een substraat is van Mrp2 (Hoofdstuk 5). Het is echter nog 
onduidelijk wat de bijdrage is van Mrp2 aan de renale uitscheiding van PAH. 
Studies met Mrp2-deficiënte en normale ratten kunnen daar meer informatie over 
verschaffen. Het beschreven celsysteem leent zich verder ook uitstekend om in de 
toekomst gemuteerde Mrp2-eiwitten te produceren en het effect te onderzoeken 
van aminozuurveranderingen op de transportfunctie.
In overeenstemming met de uitscheidingsfunctie van Mrp2 is aangetoond dat 
het eiwit zich in de apicale membraan van de levercel, de proximale niertubulus 
en de top van de vlokken van de dunne darm bevindt (Hoofdstuk 3). In alle drie 
de weefsels is dit dé lokatie voor een transporter die tot taak heeft potentieel 
giftige stoffen uit het lichaam te verwijderen. Bovendien kan Mrp2 in de dunne 
darm een rol spelen bij het vormen van een barrière, waardoor de biologische 
beschikbaarheid van bepaalde stoffen laag kan zijn. De in hoofdstuk 3 beschreven 
Mrp2-specifieke polyclonale antilichamen kunnen verder gebruikt worden om de 
invloed op het expressieniveau van Mrp2 te onderzoeken van verschillende 
pathofysiologische omstandigheden, zoals zuurstoftekort (ischemie) en toxische 
nierschade. Ondanks de beschikbaarheid van Mrp2-deficiënte ratten zou het 
wenselijk zijn om in de toekomst een Mrp2-deficiënte muizenstam te 
ontwikkelen. Een dergelijke Mrp2-knockout-muis zou gekruist kunnen worden met 
de reeds beschikbare P-glycoproteïne-deficiënte muis. P-glycoproteïne bevindt 
zich namelijk eveneens in de apicale membraan van onder meer lever-, darm- en 
niercellen. De uitschakeling van beide transporteiwitten zou meer informatie 
kunnen verschaffen over hun rol in de renale en intestinale uitscheiding van 
lichaamsvreemde stoffen.
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